U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

CENTERS FOR DISEASE CONTROL 1

NATIONAL INSTITUTE FOR OCCUPATIONAL

SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

ROCKY FLATS PLANT WORK GROUP

THURSDAY
SEPTEMBER 12, 2013

+ + + + +

The Work Group convened in the Zurich Room of the Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky, at 9:00 a.m., Mark Griffon, Chairman, presiding.

PRESENT:

MARK GRIFFON, Chairman DAVID KOTELCHUCK, Member WANDA I. MUNN, Member PHILLIP SCHOFIELD, Member*

NEAL R. GROSS

ALSO PRESENT:

TED KATZ, Designated Federal Official TERRIE BARRIE BOB BARTON, SC&A* JAMES BOGARD, DCAS* ELIZABETH BRACKETT, ORAU Team* RONALD BUCHANAN, SC&A* STEPHANIE CARROLL* JOE FITZGERALD, SC&A* DeKEELY HARTSFIELD, HHS* LARA HUGHES, DCAS* JOSH KINMAN, DCAS* JENNY LIN, HHS ARJUN MAKHIJANI, SC&A* JOHN MAURO, SC&A* DAN McKEEL* JIM NETON, DCAS LaVON RUTHERFORD, DCAS MUTTY SHARFI, ORAU Team* DAN STEMPFLEY, ORAU Team*

*Participating via telephone

JOHN STIVER, SC&A*

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

T-A-B-L-E O-F C-O-N-T-E-N-T-S 3 PAGE Welcome and roll call WORK GROUP DISCUSSION NIOSH Revised SEC Evaluation Report 4 SC&A Reviews on tritium 78 LUNCH BREAK SC&A Reviews on data falsification concerns 168 Petitioner Comments 190 WG Plans for ABRWH October meeting 193 Adjourn 193

NEAL R. GROSS

P-R-O-C-E-E-D-I-N-G-S 4
(9:02 a.m.)

(Roll call.)

CHAIRMAN GRIFFON: Thanks, everyone, for coming. And I think we have a pretty straight-forward agenda. I hope I'm going by the agenda when I say that. We'll probably start off with a presentation from NIOSH overviewing what they've done so far on four issues, I think. Four or five issues. And then NIOSH has a couple White Papers in addition to the PowerPoint presentation. And then SC&A has at least one response document. And I think — a couple papers, right.

So I think it makes sense to start off with LaVon's presentation, give us an overview and then we'll go from there, okay?

MR. RUTHERFORD: Yes, this is LaVon Rutherford. And our presentation is really going to focus on the revision to, you know, what we've done and why we've decided we're going to revise our existing Evaluation Report.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Some of the other items associated with the tritium White Paper and the data falsification will actually be discussed in further when SC&A does their review of those two White Papers.

A little background. I don't think
-- listening to the people on the phone, I'm not
sure we even need much background here. I've
prepared a little background just for if there
was going to be people that might need to know
that.

on September 5th of 2012. We presented the Evaluation Report in Denver on September 18th. Everyone should remember at that time our evaluation was focused on tritium exposures over the period at Rocky Flats up to 1989. And we recommended at that time for no Class to be added based on our evaluation.

At that time the Board made a determination that additional reviews should be done, you know, that review included classified

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

interviews, classified document reviews and such.

On the third slide, just to make it easier for people, some of the follow-up efforts that we did. We did additional data captures. We did data captures at Los Alamos National Lab, OSTI, EMCBC and DOE-Legacy Management, as well as some additional data capture at the Denver Records Center.

We had secure discussions, not only in Denver in November of last year, but also in Hanford this year, or this past August. We also did secure interviews and other interviews. We did some additional dose reconstruction modeling to try to fine-tune some of the tritium work, and we also looked at our analysis on the other issues.

As Mark had mentioned at the beginning, there were roughly four issues other than the tritium issue that we were looking at in the post-evaluation. There was some additional tritium work that we were doing, so

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

we had some follow-up efforts on that.

7

We had the evaluation of petitioner concerns. The petitioner, Ms. Barrie, brought up some potential data falsification and data invalidation that we were running down.

We also were looking at the U-233/thorium strikes, and I'll discuss that a little more in-depth why we went back into the U-233 and thorium strikes. Also neptunium. Neptunium became an issue at other sites and then that became an issue that we wanted to look back into here. And then other thorium activities.

The last three items, the thorium strikes, our U-233/thorium strikes, neptunium and other thorium activities will be included in the Evaluation Report.

Next slide. The White Paper on tritium, just again a little background. And we issued that White Paper on June 25th. The White Paper at that time again concluded the same as the original ER did, that dose reconstruction was feasible. However, it did provide a little

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

refined analysis, I guess a little more precise of what the potential chronic exposure could be to a worker.

And again we issued that paper on June 25th, provided it to the Work Group on June 26th and to the petitioner on July the 3rd. And then we presented that to the Work Group at the Work Group meeting on July 8th.

There was some preliminary discussions at that time that the report had only been in the Work Group and SC&A's hands for a very short time. And so there were a few follow-up questions, but SC&A had not completed their formal review of that White Paper.

I'll hold off discussions about that until later on in the agenda. When SC&A discusses their review I'll discuss the follow-ups that we did as well.

The second White Paper that we did was the data falsification and data invalidation. Again, this was focused on issues brought up by the petitioner. We issued

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that report on June 25th, and we provided it to the Work Group on June 26th and the petitioner on July 3rd. And then again we presented that White Paper to the Work Group on July 8th.

Again, this was another White Paper that had only been in SC&A's hands and the Work Group's hands for a very short time. So there were a few questions that were brought up that we were doing follow-up work on, but their review was not completed yet.

Okay, let's jump into -- the next slide is on the U-233/thorium strikes, and this is more focused on the revision to the Evaluation Report. U-233/thorium strikes were originally vetted under SEC-0030 evaluation. We reopened this under SEC-0192 after indications that this may have occurred more than the two times previously identified. We had actual indications that we had support for possibly five, I believe, five different strikes.

U-233 was being evaluated for its use in the weapons program at Rocky Flats. The

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

problems with U-233, not only are there internal problems with U-233 and U-232, but it also presented an external problem, the U-232, because of the progeny and the high gamma energies emitted by the progeny associated with U-232. Therefore it had an external hazard, so that presented concerns.

So because of that concern, a chemical process was developed called a thorium strike to remove the thorium 228 and its progeny, and basically to keep the external exposures down so the material could be worked with and they could, you know, do what they were going to do with it. Okay, next slide.

During the deliberations of SEC-0030, the bounding thorium dose was based on air sampling taken during the strike in 1965. So there were two strikes identified in SEC-0030. The 1965 strike was felt as bounding.

The strike was considered bounding because it had the highest concentration of U-232 of the two strikes. It was roughly 50 ppm,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

This transcript of the Advisory Board on Radiation and Worker Health, Rocky Flats Work Group,
has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable
information has been redacted as necessary. The transcript, however, has not been reviewed and
certified by the Chair of the Rocky Flats Work Group for accuracy at this time. The reader should
be cautioned that this transcript is for information only and is subject to change

if I remember correctly. No credit was taken for the ventilation, the hoods or the time limits.

Again, as I mentioned, the interviews that we had in documents indicated that strikes occurred other than the two previously evaluated. So our questions, knowing that there were additional strikes, were, okay, are these additional strikes, were they still bounded by the 1965 exposure? And, you know, could we verify that?

Other questions came up based on a recent addition of Classes at Hanford based on an inability to reconstruct doses to U-233, neptunium, thorium and highly enriched uranium.

Just a little background, the Hanford SEC, I believe it's number 201, added a Class up to 1983, and it was based on, as I mentioned, the U-233, the neptunium, the thorium and the highly enriched uranium.

We were aware that Rocky Flats had the U-233, as well as the neptunium, and so we

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

wanted to do a little comparison. Were the \$\frac{1}{2}\$ activities similar? Were the materials' quantities similar? And how much monitoring do we have in comparison between the two?

Next slide. Okay, for the thorium exposures, we've come to the conclusion that the 1965 bounding scenario that was in SEC-0030 is still, we believe, is the bounding scenario. We believe that because most documents indicate the U-233 was to be processed or shipped off-site prior to the 90-day period.

Once that hazard was recognized and in dealing with the U-233 they tried to ship the stuff offsite or process the stuff prior to that 90-day period. Again, we do know that there were additional strikes, but the attempt was to limit the ingrowth.

Documents indicate that the concentration with U-232 did not exceed 8 ppm after 1965. As I mentioned, the 1965 concentration was roughly 50 ppm, and the later years after that '65 period was around 8 ppm. It

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

did not exceed 8 ppm.

13

So we've concluded that the original scenario that was developed under SEC-0030 is still a bounding scenario.

I will mention that we did have issues with the air sampling that was used in that 1965 -- or in that previous analysis. When we looked back and looked at the air sampling, we've come to the conclusion that the air sampling that was used in the previous analysis was not the right air sampling.

What we did, though, is we requested additional air sampling from the site and for that existing period and for the correct building. And then we used that air sampling and to revise our exposure, that That'll included scenario. be in the So we came to the same Evaluation Report. conclusion, but we had to use different air sampling in doing that because we believe the air sampling originally done was not correct.

Okay, the next issue associated with that,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

other than the thorium strikes, the thorium issue, was the U-233 exposures. As I mentioned, this was an issue at Hanford, and under the Hanford recommended Class we wanted to look back at this and ensure that we had a good method for identifying U-233 exposures and encompassing when needed in dose reconstruction.

The quantity of U-233 onsite at Rocky Flats varied from 1964 to the end of U-233 operations in 1983. Again, this was being evaluated for use in the weapons program at Rocky Flats. Estimates from available documents indicate quantities could have been from 1 kilogram up to 150 kilogram from 1965 through 1983. The highest quantities from 1965 through 1968. Bioassay data for uranium exists and a uranium coworker model exists for the period of concern. No specific bioassays associated with U-233.

You know, initially, our idea was that we would use the uranium bioassay data and look at the uranium bioassay data and we would

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

assign the U-233 doses to anyone that had uranium bioassay, based on the idea that if they were working with U-233 they were probably uranium bioassayed.

So in order to, you know, approach this, we thought we needed to come up with some type of validation or way to ensure that workers that were working with U-233 did actually receive -- did actually have uranium bioassay.

We have a logbook from a specific period of U-233 operations that listed names. There were 46 names of individuals that worked on the U-233 project for that specific time period in the logbook.

I want to make sure everyone understands that those 46 individuals, it's not reasonable to assume that those 46 individuals were the same 46 individuals that worked from 1964 to 1983, but it gives you an idea.

We've got 46 individuals. If we could go back and we have a portion of those in NOCTS, that we can look at their internal data

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

sets and see if they had uranium bioassay, we could make the assumption, okay, yes, good. At least we know -- our first step in validation is that these workers that were working on the project that are claimants had uranium bioassay.

Well, we went back, we have 18 of the 46, believe it or not -- which is a pretty high number; I was kind of surprised -- 18 of the 46 are claimants at this time. Now, of those 18 claimants, though, 17 had uranium bioassay. So there is one individual that did not have uranium bioassay over the period in his file, not over any period. And we could not come up with a conclusion or a good reason why that individual did not have uranium bioassay. So that put a little hole in our initial idea of using uranium bioassay for the individuals.

So as I mentioned -- next slide -- indications that not all workers working on U-233 operations had uranium bioassay. We had this small sample set of individuals and we have one individual that did not have uranium

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

bioassay with no real good reason why he did not;

The problem with that is, is that forces us to assume then that all workers that we would use a uranium coworker model for, we would have to come up with a method with -- including the U-233 and U-232.

And the difficulty with that is, is that means that you're going to have a factor, an adjustment factor in doing that. And also the activities of U-233, and Jim will jump in if he needs to, associated with U-233, because of the very high specific activity similar to like plutonium, it was dealt with differently.

And using the uranium, standard uranium operations in support of a coworker model for that type doesn't necessarily make sense, okay? Jim, do you want to add anything to that?

DR. NETON: No, I think that's true.

It's a different activity. I mean, it's short duration projects targeted, you know, with specific activity almost equivalent to

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

This transcript of the Advisory Board on Radiation and Worker Health, Rocky Flats Work Group,
has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable
information has been redacted as necessary. The transcript, however, has not been reviewed and
certified by the Chair of the Rocky Flats Work Group for accuracy at this time. The reader should
be cautioned that this transcript is for information only and is subject to change.

plutonium, it's just much more active. So there is no good reason to believe that the coworker model we established using natural uranium, depleted uranium type exposure, even HEU exposures, would be valid for those operations.

It's almost like a pure stratification issue. I mean, this is a purely isolated operation that, like I say, I wouldn't be convinced that the coworker models would be appropriate.

CHAIRMAN GRIFFON: Was that the initial argument, though, was to use the coworker model?

DR. NETON: Yeah, and the interesting thing, there's two coworker models for Rocky Flats. There's a mass model and a gross alpha model. Well, obviously the mass model would give you ridiculous numbers because it referred to mass activity.

And then you would end up using the gross alpha model, the alpha urine model. But, again, that model is based predominantly on sort

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

of other operations that weren't necessarily this U-233 strike activities. So what's to believe that the 50 percentile, or we use the 95th percentile actually at Rocky Flats, 95th percentile, that model is valid for this other operation?

We also don't know that everybody was bioassay, even though there's 17 out of 18 people that we knew worked on the project had bioassay samples, you always run into the situation about ancillary support work or clean up.

I mean, it's pretty clear that people that were directly making materials looked like they had good bioassay coverage, but after the operation's over, the clean-up crews go in, that sort of thing, you really have no idea. That's our thinking at this point on U-233.

MR. RUTHERFORD: So DCAS management did not feel this was sufficiently accurate and quantities, activities, and available

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

monitoring were similar to a similar period 25 Hanford where DCAS determined dose reconstruction was not feasible. Again, this is roughly the exact same time period as what we added the Class for at Hanford for similar activity.

Neptunium. I'm going to jump from the U-233/thorium to neptunium. General conclusion under SEC-0030, our original evaluation was neptunium was used in small quantities for research-type work and had limited exposure potential compared to uranium and thorium.

A determination was made to re-explore this exposure situation based on interviews and recent determinations associated with neptunium, U-233, and thorium at Hanford. Next slide, please.

Records indicate that neptunium was processed at Rocky Flats as early as 1962 and inventories existed until 1988. And, you know, we believe 1962 was the earliest based on what

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

we've seen in the neptunium processing, there by a document that's out on neptunium processing. There could be questions on that just because it wasn't a special nuclear material until 1985.

Neptunium was processed to produce pure neptunium oxide, metal, and metal alloys. The processes employed included dissolution, anion exchange, precipitation, filtration, calcination, conversion to fluoride, and reduction to metal.

So you basically went through the whole metal production process. So fabrication steps such as casting and rolling were performed to produce metal shapes and foils. It was also recovered from residual materials including sand, slag, crucibles, casting skulls, and alloys.

These residues were not only generated from operations at Rocky Flats but at Lawrence Livermore, and I believe Savannah River as well had operations that -- I know Lawrence Livermore did, but other sites provided residues

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

for Rocky to process.

22

Based on documents and inventories, it appears most work with neptunium was completed by the end of 1983. If you look at when the neptunium processing report that was done by Rocky Flats, it was done shortly after — I think it was 1983 or '84. But it was right in that time period and operations are indicated in a past tense manner.

All inventories, when you looked at the NMMSS database as well as the MC&A database, there were still inventories of neptunium at Rocky Flats but they're virtually constant. I mean, they're small gram -- I mean, single gram differences, but nothing to indicate to us that there were operations past 1983.

Annual onsite inventories were typically maintained around 1 kilogram. And I emphasize on this that this does not address throughput. You know, if you looked at the inventory and then when we went to the NMMSS database out in Hanford, you know, they changed

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

over the periods that we would see, the quarter by periods or other periods we would see, but it was typically maintained around the 1 kilogram time.

If you looked at it, they had, you know, the batches did not typically exceed 300 grams, but there's no real way to -- how many batches actually were processed, how much material went through.

We didn't actually have the material sheet records where they, you know, shipped this amount out to say that, you know, there was 1 kilogram throughput in a year. You know, based on what we read, it looks like there would have been significantly more than that.

Buildings having neptunium inventories included 371, 559, a number of buildings as you can see on the presentation. And the reason why there were a number of buildings, they had so many different little operations and methods that they were doing, little things with neptunium. So, you know, that's why it's not just in one single R&D area.

10

11

12

13

14

15

16

17

18

19

20

21

Neptunium exposures, in the particle neptunium processing document you will see there's a statement in there that documents indicate some early work was conducted in open hoods, but most work was performed in glove boxes.

So, you know, we have the early work that we know had the potential of open hoods and then later work with the glove boxes. Based on review, neptunium exposure potential existed in every processing step including extraction purification, and hydrofluorination, reduction metal, to alloying, casting, and rolling.

The data that we have on neptunium, there are two bioassay samples. These were taken in 1966. One was listed as below the significant level and the other was a 0.9 dpm per 24 hours.

And then we have gross alpha bioassay samples existed up until 1970s. What happened was, at the time gross alpha was used

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

as -- kind of used for workers that were working in both uranium and plutonium areas.

If you remember, at Rocky, the early years at Rocky, uranium was their main focus and then shifted over to the plutonium work. They were doing the gross alpha. It allowed them to, if they had a large spike on a gross alpha they could do a plutonium analysis on it to see if it was actually a plutonium exposure. It was kind of an indicator as well.

So workplace monitoring data, we have found no workplace monitoring data specific to neptunium operations.

The reason why I pointed out the gross alpha was we looked at, you know, the initial idea was to use the gross alpha as an indicator for plutonium. If you have all your alpha-emitting radionuclides in this gross alpha sample, we ought to be able to -- if we could assume or if we had the concern that an individual worked with neptunium, we could apply that gross alpha from a neptunium exposure.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

The problem with that was we were concerned that the actual analysis technique or the chemical process may have potentially stripped out the neptunium, since their focus was typically uranium and plutonium. And so we wanted to, one, go in and see if they were using a gross alpha as an indicator for exposure to other radionuclides, to other alpha emitters.

So we interviewed two former Rocky Flats plant employees, both of those, one who was in charge of the bioassay program from 1961 until -- and I can't remember the dates -- in the '80s, and then another who was a main player in the RADCON program itself. And we interviewed them to want to ask them, were you using the gross alpha as an indicator for neptunium? And if they said no, did the gross alpha, did you have the ability to see the neptunium in the gross alpha?

When we interviewed both of these individuals, you know, both of them had concerns with being able to -- the actual neptunium

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

following through in the co-precipitation process.

The way they, initially, up until 1961, the bioassay samples, all the bioassay samples were completely ashed. And so all your alpha emitters would have stayed in that solution. But the problem with that, it took a considerable amount of time.

And so the individual that we interviewed actually came up with this co-precipitation process where they would basically focus the samples, and in that process — and that individual, he said he couldn't be for sure but he questioned whether the analysis would support identifying neptunium.

MEMBER KOTELCHUCK: Excuse me, I don't know what you mean by focus the samples.

MR. RUTHERFORD: Well, you know, and I'm definitely not the best at internal dosimeters, but I will say that they were looking at, you know, uranium and plutonium mostly. So the analysis was to focus, to get the sample to

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

a point where it would be easier to see the uranium or plutonium.

Would you agree, Jim?

DR. NETON: The analysis was optimized to precipitate the plutonium and the uranium, not with any concern about the ability of neptunium to also come down. It could have, but no one knows. No study was done.

MEMBER MUNN: So basically we have no gross alpha that is actually gross alpha?

DR. NETON: After certain dates.

MR. RUTHERFORD: Exactly. And it's -- well, we can't be for sure it's all gross alpha, exactly. It's kind of gross alpha for plutonium and uranium. That's what it --

MEMBER MUNN: And these folks who put this together didn't have any real concept of what alpha emitters they were stripping out of their sample? They're just saying they don't know.

MR. RUTHERFORD: They don't know. It could have been in there but they don't know,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

because they weren't, you know, they weren't looking at that. And when we talked to both of them, they said, you know, we really weren't looking for that.

MEMBER MUNN: No, but you don't have to be looking for it.

MR. RUTHERFORD: Sure.

MEMBER MUNN: There's nothing in my education that prepares me for gross alpha not being gross alpha.

MR. RUTHERFORD: I understand.

DR. NETON: Well, but they had a specific chemical procedure that would bring out the plutonium and the uranium. They didn't optimize it at all for anything else, so it was optimized for precipitating out the plutonium and uranium.

MEMBER MUNN: When did they start this and when did they stop it, if they ever did?

MR. RUTHERFORD: Yeah, they started it in 1961 and they stopped gross alpha, period, in 1970. And our original approach was we were

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

going to look at using the gross alpha up untibe that 1970 period, and then, if we could use that up to the 1970 period, we would look at, is it feasible to say that -- because after 1970 we really had nothing to hang our hat on.

But we were looking at, can we use that early period of gross alpha and say, based on engineering controls and the program, that we can extrapolate it to the later years? But there ended up being two holes with that problem, two holes with that idea, let's put it that way. One, the gross alpha we couldn't use.

The other end of it, when I went to Hanford and looked at the NMMSS database and looked at the inventories, the inventories didn't support that idea. Meaning that if you're going with the idea that the controls and everything are in place, it works if it looks like the operations and everything were constant and you were doing the same types of things. But there were large fluctuations in inventories after 1970 that I would struggle saying that the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

activities stayed exactly the same. 31

MEMBER MUNN: At Rocky Flats.

MR. RUTHERFORD: At Rocky Flats. At Rocky Flats specifically, yes. And the reason why I'm saying at Hanford -- and you guys are probably wondering. The reason we went to Hanford, Hanford now has an ability to review classified documents electronically.

And so these classified documents from the NMMSS database were sent to Hanford for our review electronically, and from the NMMSS database. And so I was able to look at inventories of not only neptunium, but U-233 and thorium in that classified environment.

MEMBER MUNN: And Rocky Flats inventories of neptunium are not adequate for us to determine a bounding dose on neptunium?

MR. RUTHERFORD: Well, you're saying -- are you looking at a source model, a source term model?

MEMBER MUNN: I'm talking about a potential source model, yes.

NEAL R. GROSS

10

11

12

13

14

19

16

17

18

19

20

21

MR. RUTHERFORD: Well, I'll talk about that here in just a second, actually. And I'll be specific on that one too.

MEMBER MUNN: Okay.

MR. RUTHERFORD: So we have little to no personal area monitoring. Gross alpha bioassay can't be used as a viable means. We have too many different activities. And here's where I get into why a source term model is difficult.

You had wet, dry processes. You have many different chemical forms that you were dealing with, with the neptunium. It was alloy, it was oxide. It was, you know, nitrate solutions. And so it was many different chemical forms. And then it was processed in many different ways.

You know, they recovered the residues, and there wasn't a single method for recovering residues. There were three or four different methods. There were different methods for actually producing materials that

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

they used.

10

11

12

13

14

19

16

17

18

19

20

21

22

33

So with so many different operations and the chemical forms being different, it would be very hard to come up with a source term model that would support all these activities. Do you agree, Jim?

DR. NETON: Yes.

MEMBER MUNN: Well, I can understand how it would be difficult to identify, for example, a minimum. But I don't understand why it would be difficult to identify a maximum, regardless of the form, regardless of the process. Neptunium is neptunium.

MR. RUTHERFORD: I agree.

MEMBER MUNN: And if you have an adequate inventory, regardless of the process and regardless of the form, you ought to be able to establish a maximum. The only question that resides then is, is the maximum sufficiently bounding to be able to use it?

MR. RUTHERFORD: And I agree with you. The only problem you've got is those

NEAL R. GROSS

inventories were annual inventories. That inventories inventories inventories. That inventories inventories inventories inventories of the material.

We don't have a mechanism. I mean, there's probably a way, I'm not sure, to go back and look at all the material shipped off-site versus all the material that came onsite to determine the throughput from the site. that's what it would take to determine the throughput in order to come up with that bounding exposure scenario. Because you had operations that would use 300 grams, but we don't know how many times they did that, you know, over a year, like I said, you know, they were because producing material. They were getting material. They were getting residues from other sites. we have inventories in different, And so specific time periods, but we don't know the throughput between those time periods. that make sense?

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MEMBER MUNN: The probability that it exceeded a kilogram is what?

MR. RUTHERFORD: You know, I just don't know.

DR. NETON: But if you get to a kilogram, I mean, it doesn't sound like a lot of mass, but activity-wise it's substantial. Hundreds of millicuries, I don't know, I haven't done the calculation, but the specific activity is pretty high.

So you have a very large amount of potential for intake from this material. It wouldn't be like if you just had a kilogram of uranium.

MEMBER MUNN: I understand.

DR. NETON: So this is not unlike what we've encountered, what I would call the exotics, at other facilities. I mean, it turns out that Rocky Flats had some exotics out there that we're not able to develop models for as well. I mean, the neptunium was not considered in the first Evaluation Report.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MEMBER KOTELCHUCK: Tell as a little about where they got their neptunium before or the raw material from that they processed.

MR. RUTHERFORD: I mean, most of it was processed from residues or they received it from other sites. And it wasn't, you know, so good.

MEMBER KOTELCHUCK: So it was already worked on at other sites?

MR. RUTHERFORD: Well, to a degree. I mean, sometimes it was worked on, you know, and sometimes they would receive it as a residue or a by-product in material, have to extract from that by-product then get it into the right form that they want to produce the metal. Okay, so they fluoride it and so on.

MEMBER KOTELCHUCK: So you could not rely on how much, really, was coming in because it was a residue within something else?

MR. RUTHERFORD: Yes. And I could -- you know, if I knew what percentage of that material it came in and the quantity, and I could

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

come up with how much was produced, but every shipment that comes in, doing that and trying to come up with that would be really tough.

That would be hard to do, I can tell you. Just because, you know, I'd have to go back and I'd find all the shipping records of every time that residues were shipped to Rocky Flats that contained neptunium, and then from that determine how much, possibly, the neptunium was retrieved from that residues and then processed.

And then you had neptunium that was worked on the site and had residues picked up onsite and reintroduced into the system as well.

I don't know what to add to that.

MEMBER MUNN: It's hard to believe that all of the badging that was done and all of the bioassays that were done are worthless. It is just impossible for me to accept that nobody can say anything about all of the science that was done at Rocky Flats. It's hard to accept that. If I have to accept it, I guess I have to accept it.

NEAL R. GROSS

10

11

12

13

14

19

16

17

18

19

20

21

MR. RUTHERFORD: I recommend, à≴ you get a chance, to read the interviews with the two individuals. And these are very, I mean, well-educated, top of the line --MEMBER MUNN: I understand. MR. RUTHERFORD: -- individuals. I would recommend reading those, because --MEMBER MUNN: I understand. DR. NETON: And neither indicated there was any intention of monitoring workers for neptunium. And, you know, I MR. RUTHERFORD: interviewed Leo Faust, who worked program, who worked out at Hanford, and I'm not one of -- I shouldn't say his name on there,

(Simultaneous speaking.)

MR. KATZ: You're okay.

MR. RUTHERFORD: And I interviewed Leo because working at Hanford, you know, and dealing with the same thing. And Leo said, you know, we had small operations going on with

NEAL R. GROSS

should I?

10

11

12

13

14

15

16

17

18

19

20

21

neptunium and our focus was not neptunium. Ogg focus was the plutonium work and the other work that we were doing onsite, and so -- yes.

CHAIRMAN GRIFFON: But to argue Wanda's side for a change.

MR. RUTHERFORD: Sure.

CHAIRMAN GRIFFON: I mean, did they not monitor for neptunium because they felt like it was just not that big of a hazard or that, you know, they had programs in place, that potential doses were so small? I mean, I think it --

MR. RUTHERFORD: Yes, I would say it's probably true, but --

MALE PARTICIPANT: I'm not sure though. Well, maybe --

MR. RUTHERFORD: The problem you've got is, though, you only have two bioassay samples and one of them is positive, okay. And we know they worked in open hoods.

DR. NETON: You've also got to look at the monitoring programs that were in place.

I mean, for example, the thorium strike

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

operations. If you look at that, they did some monitoring there because they're worried about the thorium issues.

But, you know, their conclusions were that these were very small exposures because they didn't exceed 50 percent of the MPC. And so that was the mentality then, which was not to keep doses ALARA or, you know, worry about health endangerment, but did we exceed the maximum permissible concentration in air that a person could breathe every hour for a whole work year? I mean, so that was a slightly different mentality.

MEMBER MUNN: But it wasn't a reasonable mentality.

DR. NETON: I'm not saying it wasn't, but then if that's your monitoring mentality then how do you know why they did or did not monitor the neptunium operations? They could have said, look, this is a short duration project. It could exceed a huge amount, but it's only for ten hours so we're not worried

10

11

12

13

14

15

16

17

18

19

20

21

about it, as far as exceeding any exposume limits. But how we would bound that I don't know. I mean, it would be a quesstimate at best.

CHAIRMAN GRIFFON: Well, get through neptunium and then the other thorium. And then I have some questions on the thorium strike stuff, and then we'll go back and have some chance for questions.

MR. RUTHERFORD: Okay, so, again, quantities and activities associated with neptunium at Rocky Flats are similar to the Hanford during the same time period, as I mentioned. Based on this, NIOSH has concluded dose reconstruction is not feasible for neptunium exposures.

Other thorium issues. You know, in SEC-0030, the NIOSH position was that documents supported that thorium quantities present at Rocky Flats were not in high enough quantities to contribute significant to internal dose potential. And, you know, this statement was taken out of our original evaluation.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Beginning in 1952, thorium was usqq onsite in quantities small enough that effluents were not routinely analyzed for thorium. Thorium quantities vary from as little as none to as much as 238 grams in a given month --

DR. NETON: Kilograms.

MR. RUTHERFORD: -- kilograms, I'm sorry, in a given month. Okay, so zero to 238 kilograms in a given month. The principle use was fabrication of metal parts from natural thorium metal and from various thorium alloys.

Thorium oxide might have been used as a mold-coating compound in limited experiments. And thorium compounds were used in analytical procedures. Most of the work associated with thorium during the SEC-0030 evaluation was focused on specific activities that occurred in the '60s.

The ingot work, the thorium strike work, everything that was originally looked at was post-1960. You know, our concern was we want to look at and see -- we had indication that

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

thorium was onsite prior to 1960 all the way baqk to 1952.

So based on interviews and document review, NIOSH decided to reevaluate the thorium issue, especially for the early years. We could not find any specific reports or documents that supported other activities occurring other than what were previously identified.

The problem we had is that we do know inventories of thorium existed back to 1952. We looked at those inventories and we've seen that. And those inventories changed. It was not just one year. I mean, it wasn't every year the same inventory type thing. The annual inventories changed at a point where it would give you indication that there was some work going on.

Again, we don't know what that work is, but we do have indication that there were other work going on. We know that there was things that were mentioned in the previous evaluation, that those activities could have been going on, but again we haven't seen any

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

additional documentation on that.

44

We do know that, based on the review of the NMMSS database, that thorium was pretty much nonexistent at Rocky Flats after 1971, at least from an inventory perspective.

And so, really, the only thing I want to say right now on the thorium is we're still looking at the early years of thorium use at Rocky Flats. We're trying to finalize our position on that.

Again, we have nothing that's identified, really -- I would say nothing that's really identified new activities. It's the question of with the inventories changing in those early years, which gives you an indication that there was activities going on with it, you know, what do we do with that?

Our revised Evaluation Report, again the current SEC Classes are from April 1, 1952 through December 31st of 1966, and it's for all employees who were monitored or should have been monitored for neutrons.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Based our inability 49 reconstruct U-233 and neptunium, we will be recommending a Class at the October Advisory Board meeting. The parameters of that Class recommendation have not been fully determined but they will include the years previously discussed for U-233 and neptunium operations. Like I said, it may just be 1962 through 1983. We just haven't finalized this one portion. CHAIRMAN GRIFFON: Can you go back to the slides on your next to last Other Thorium slide?

MR. RUTHERFORD: Yes. Is that the right one?

CHAIRMAN GRIFFON: Yes. Can you just -- I might have missed it. I might even be reading the previous slide. But can you go over that again? I mean, you're saying that --

MR. RUTHERFORD: What we were looking for was something that said -- we were looking for documents or reports that indicated a specific other work that was going on in the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

early years associated with thorium. And we didn't find anything other than what was previously discussed in SEC-0030. There was, you know --

CHAIRMAN GRIFFON: Oh, okay, other activities.

MR. RUTHERFORD: Right.

CHAIRMAN GRIFFON: Okay, because the next bullet confused me.

MR. RUTHERFORD: Yes.

CHAIRMAN GRIFFON: You're saying you do have inventories?

MR. RUTHERFORD: We do have indication that inventories changed in those early years. And so --

CHAIRMAN GRIFFON: So you're just continuing to look for --

MR. RUTHERFORD: Yes, we're looking at this and -- there's changing in inventories. You know, do we feel like what we did under SEC-0030 is still appropriate? And that's what we're trying to finalize right now.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

CHAIRMAN GRIFFON: All right Well, go ahead. Let's start with Terrie, if you have something.

MS. BARRIE: Okay. I just have a quick question on the other thorium issues. Our favorite, the magnesium-thorium alloy plates?

MR. RUTHERFORD: Now, the magnesium
-- and I don't know if you heard me there at the
very end when I said based on what's in
inventory. Magnesium-thorium alloy, I doubt
that it was inventoried as part those
inventories, all right.

We have not looked -- and I will say we have that issue on our plate to look at that. But our focus over the last few months has been to get to a point where we could be ready for a meeting in October to discuss, you know, the Evaluation and the changes.

So that's still on our plate. We have not had a chance to run that magnesium-thorium alloy issue down again.

MS. BARRIE: And I just have one

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

other thing if that's okay. And I don't know 18 this is accurate or -- it's accurate, but if it's applicable. I have an inventory list for thorium nitrate. In 1974 there was three kilos, and 1988 there was 3.754 kilos. And I don't know if you'd like this?

MR. RUTHERFORD: Yes, I'd like to keep this.

MS. BARRIE: Okay, thank you.

DR. NETON: I mean, we do know those thorium inventories in those years. I mean, that's not in debate, really. It's really what they did with this material.

CHAIRMAN GRIFFON: What were the activities, right.

MS. BARRIE: Okay, thank you.

CHAIRMAN GRIFFON: LaVon, can you summarize, I mean, to help my memory, but also for David, just the magnesium-thorium alloy question?

MR. RUTHERFORD: Yes.

Magnesium-thorium alloy was back when we were

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

doing an evaluation of Dow Chemical in Madisong,
And one of the operations for Dow was producing
magnesium-thorium alloy.

And originally -- and we do have one of the main players on the line -- but originally when Dow was designated as a facility under this program, it was designated because of the uranium work that occurred at Dow in the 1957 to 1960 period. Well, at the same time Dow was producing magnesium-thorium alloy. Later on it was determined that that magnesium-thorium alloy could have been used in weapons program, and because of that it was added as a covered process or covered under our program.

And so then the question came up that, you know, that people believe, workers believe that magnesium-thorium alloy was shipped to Rocky Flats and used at Rocky Flats.

And so I know Terrie's given me at least one document in reference to this for us to look at.

And so the question is, is if magnesium-thorium alloy was shipped to Rocky

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Flats and used at Rocky Flats, is there exposure potential from that magnesium-thorium alloy under Rocky Flats' issue that we need to reconstruct? And so we're still running that one down.

DR. McKEEL: Chairman Griffon, this is Dan McKeel. Could I make a comment?

CHAIRMAN GRIFFON: Sure, Dan. Go ahead.

DR. just wanted to McKEEL: Ι clarify information the new about magnesium-thorium that keeps this off the radar So what LaVon just said is basically true about the original discussions related to SEC-0079 and Dow Madison. However, recently, within the past year, Terrie Barrie got an anonymous tip from a Rocky Flats worker who desires to be anonymous that the use of the magnesium-thorium alloy plates at Rocky Flats was specifically that it was used in, quote, "the mod center."

And this person said it was used in

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Building 881 and it was used on Pad 903, and this is pretty much a quote from the tipster, "to shield," or "bulletproof," I think was the term they used, "semi-trucks and railroad cars in the mod center."

Well, that led to a long chain of events which has included high level discussions with Department of Energy, Legacy Management, with their environmental management who has looked a little bit into classified records.

And also research that we've done on the Internet, where it's very easy to find under historical engineering records that as a matter of fact the mod center, which is actually -- the name of that really is the Transport Modification Center, and it was located at least for awhile in Building 440 at Rocky Flats, and in fact the HAER Library of Congress entry on the Internet clearly shows a photograph of the room in Building 440.

It has railroad tracks running through and a railroad boxcar sitting on the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

tracks. And the legend to that, which I'yo supplied to everybody -- NIOSH, the Board, the Work Group, and Terrie and I have done that -- clearly says that what was done in the mod center at that room is to retrofit semi-trucks and railroad cars with some kind of material.

Now, the HAER, which is an acronym for the Historical Engineering Records project, does not indicate exactly what material was used in Building 440.

with However, armed that information, which is highly specific and can be immediately confirmed right now on the Internet as giving credibility to that tip, led us to petition Department of Energy, to summarize a lot of work, to look harder, including the classified records, to verify this now even more information specific about how magnesium-thorium alloy, particularly HM 21A, HK 31A was used, and if it was used at Rocky Flats.

And so Ms. Barrie and I have two FOIA

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

requests of, I would say, a large magnitude pending with both NNSA and with DOE-Legacy Management. The fees for the search, for the first one, were originally said to have been \$6,250, which we had to pay or the FOIA request would be cancelled. I appealed, and I was very, very happy that Department of Energy has decided to waive those fees.

So both of those FOIA requests are ongoing. And I'm really very upset, to be quite honest with everybody, that this information has been conveyed. The pictures have been conveyed. The information is very, very specific. And as far as I can see that shouldn't take a lot of effort to look into that.

And here I listened this morning, and specifically to hear whether that particular set of new information was going to be brought up, and it wasn't until right now when Ms. Barrie had to bring it up.

So I don't know where the priorities are, but I would say this is very, very old

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

business. I reiterate to you that we have 11 sworn affidavits from different people at Dow Madison who swore that they saw marked shipments going to Rocky Flats of truckloads of these large magnesium-thorium alloy plates.

And even I have wondered over the years, what in the world could you use that for? It's kind of hard to believe that that was used in a nuclear weapon, per se, or that they cut little pieces out to make little parts.

So those Livermore documents that led to Dow Madison being a AWE site may not have anything to do with this usage at all.

However, when you hear that there was a material used to bulletproof, and we don't know whether that means actually to protect those rail cars and semi-trucks from attacks with guns and missiles or whether it actually means to shield them from the radioactive material that we do know Rocky Flats shipped away from that site by the truckloads for many years, including up to 2006 when the site was finally

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

decommissioned.

right, Dan.

1(

11

12

13

14

15

16

17

18

19

20

21

22

55

So that's where things stand. I really hope the Work Group, that NIOSH, and everybody, will work harder to find out -CHAIRMAN GRIFFON: Yes, you're

DR. McKEEL: -- and once and for all, shed some light on that pretty clear-cut testimony from many workers.

CHAIRMAN GRIFFON: You're right, Dr. McKeel, and thank you for adding to that, because that's why I asked LaVon to -- we're not going to lose track of this issue. But that's why I asked LaVon to give a little background, and thank you for adding that.

Can I ask one question, Dan?

DR. McKEEL: Sure.

CHAIRMAN GRIFFON: Did the tipster give any time frames on when these activities were occurring?

MS. BARRIE: No, not really, no.

CHAIRMAN GRIFFON: Not really.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1	All right. 56
2	DR. McKEEL: No, we don't have a
3	handle on that.
4	MS. BARRIE: We were thrilled to get
5	
6	CHAIRMAN GRIFFON: Yeah, no, I
7	know, it's very specific, and you're right, and
8	NIOSH will pull that thread, I'm sure.
9	MR. RUTHERFORD: Yes, I want to
10	assure Dan that I had no intentions of glossing
11	over the magnesium-thorium issue. That issue
12	is on our plate, we're following it, and as I've
13	told Terrie, that we will look into that. And
14	later on in the discussion that would have came
15	up.
16	DR. McKEEL: I understand that,
17	LaVon. I simply thought it was very important
18	to get that on the official record at this point.
19	CHAIRMAN GRIFFON: Yes, thank you.
20	DR. McKEEL: Thank you.
21	CHAIRMAN GRIFFON: That was good,
22	yes. Can I just go back to the thorium strike

information? I mean, I just wanted to get some clarification on some things, because, you know, I think it's important that we understand -- it seems like it's definitely a change in position from what you had in the first SEC.

And so, you know, when I read things like you were only able to find 17 of 18 claimants, I mean, I could see that presented differently saying we found 17 of 18, you know, and therefore we've got everybody monitored pretty much, you know, and the one was a supervisor and likely not involved.

MR. RUTHERFORD: No, he wasn't.

CHAIRMAN GRIFFON: Okay. I mean, I think it's important that we --

DR. NETON: I agree. That's a little bit confusing when it's presented that way.

CHAIRMAN GRIFFON: Okay.

DR. NETON: In my mind, the idea is that you really don't know if everybody was monitored. You had no routine monitoring

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

program for this that we know of. They happened to have uranium bioassay. Whether that uranium bioassay was specifically for the U-233 operations or they just sort of coincidentally had uranium bioassay because they were working in an area that required it, we don't know.

And then you couple that with the fact that the coworker model that we have is not driven by these unique activities, this high specific activity U-233.

CHAIRMAN GRIFFON: Right.

DR. NETON: We also have to remember that most of our focus on the U-233 operations was the thorium strikes. That was the focus. And we really didn't pull the thread on the U-233 operations, which was really more of an ongoing concern.

Thorium strikes occur, as you know, periodically because of the contaminant it would grow in. And whether there was two or five, you know, I don't know how many there were, but the reality ongoing was this U-233 sort of

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

production operation where they would make --5 don't know what they made. And I don't know how many of those operations actually occurred.

Do we even know how many times they, you know -- we know that it occurred in a number of buildings and it's essentially a mini --

CHAIRMAN GRIFFON: So we sort of overlooked that in our first --

DR. NETON: Exactly. You know, because the thorium strikes was really the focus.

CHAIRMAN GRIFFON: Yes.

DR. NETON: But ongoing was this U-233 thing with material that has a specific activity of plutonium, so it's pretty hot stuff.

CHAIRMAN GRIFFON: Oh yeah. Okay.

DR. NETON: Like I said, that's the idea here.

CHAIRMAN GRIFFON: Right. And I think that's also going to be important. I mean, when you make the presentation, and it sounds like you're going to write this up and

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

make your presentation at the full Board meeting.

DR. NETON: Yes.

CHAIRMAN GRIFFON: And I think it would be good to lay out, like, there was that previous position but, we learned, we have new information.

DR. NETON: Yes.

CHAIRMAN GRIFFON: I think the Board needs to understand that.

DR. NETON: It's such a new investigation into it. I mean, I think the original ER is probably fairly silent on reconstruction of U-233.

CHAIRMAN GRIFFON: That's right.

I think you're right.

DR. NETON: I don't recall -- I think it was all focused on thorium strikes that involved U-233, but I raised the question early on. If I remember it, I said, well, heck with thorium strikes, how are we reconstructing U-233? And then we kept pulling that thread and

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

eventually it led to this, well, we don't known CHAIRMAN GRIFFON: Okay. I just think we need to be clear. We'll come back to this.

MR. RUTHERFORD: I'll make sure that's said.

CHAIRMAN GRIFFON: Yes. Go ahead, David.

MEMBER KOTELCHUCK: On the neptunium, basically you have the annual inventory about kilograms. And what you said was, in terms of what was coming into the plant, that you used the word "hard." It was hard to estimate what was coming in.

I wonder if it was possible to sample a couple of particular years to see how much was coming in. I would be more persuaded about the inability to use sourcing if I thought that in fact a lot more was coming in than a kilogram in the course of the year. Because then the one kilogram wouldn't mean that much, or wouldn't be a good estimate of the sourcing there.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

And I realize there are lots <code>@f2</code> different ways that they're using the neptunium. But, again, if I thought that there a number of years where the one kilogram represented only a small fraction of the source material that was there that year, then we really don't know anything about the neptunium.

MR. RUTHERFORD: Yes, and one, I really don't think that's possible and I'll explain why.

MEMBER KOTELCHUCK: Okay

MR. RUTHERFORD: One, I don't know if you heard me mention or if I mentioned it. Maybe I was just thinking it. Neptunium did not become a special nuclear material until roughly 1984-85, all right.

One of the documents that we read was, it said that updating the databases to get specific inventories of neptunium once it became a special nuclear material would be very difficult and we would question the accuracy.

Now I say that because, you know, so,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

one, I have a little question with the inventory that we already have because of that document. And the other issue is, I mean there's probably records that exist but I don't know how you would be able to take all the records for a given year of shipments coming in. You would have to break down and find out how many of those shipments have neptunium.

MEMBER KOTELCHUCK: Because it was not listed as neptunium, it was a contaminant of something else?

MR. RUTHERFORD: I mean, yes, it was listed as a contaminant because that's what they were getting it in to recover that neptunium, so it was listed. I just don't know that you would be able to pull together a decent number.

MR. FITZGERALD: LaVon, this is Joe Fitzgerald.

MR. RUTHERFORD: Yes.

MR. FITZGERALD: The other thing I would add is that Rocky was a center almost within DOE for the processing and recycling of

NEAL R. GROSS

10

11

12

13

14

19

16

17

18

19

20

21

neptunium.

10

11

12

13

14

15

16

17

18

19

20

21

22

64

and I think one thing that LaVon said earlier that adds to this conundrum, if you may, is that there was a myriad of activities on site. That they were, you know, not only doing fabrication of all kinds of different things whether it was foils, whether it was, you know, small items, coatings, I mean it was a whole bunch of things.

And they did it in all these different buildings and it really was a bunch of different activities, a large scope of activities that, you know, one would have to account for.

I don't think the -- certainly the quantities don't appear to be high per activity, but getting a throughput for the site is one thing. Getting a throughput for actual operations would be another thing.

DR. MAURO: This is John Mauro.

Can I ask a question related to this issue related to trying to bound exotics that we run

NEAL R. GROSS

into quite often?

65

And I recall on a number of occasions where OTIB-18 and OTIB-33 were used, where you were dealing with radionuclides, you knew that there was a good health physics program in place, and a decision is made using those OTIBs to say that well, there's a level of confidence that there might have been some exposures, but if there were any they were well below some level of MPC hours.

In other words I'm coming at the problem the opposite direction. Rather than trying to come up with throughput and let's say model, I know on occasion you took advantage of the fact that there was in fact a good air sampling program.

There was good documentation that was in place, and you would use, I think it's 18 and 33, which goes to MPC hours as a way to place a plausible upper bound on any work it might have experienced. Have you considered that strategy for bounding neptunium, for example?

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

DR. NETON: John, this is Jim. 6 don't recall ever using that type of an approach for an exotic. I know we had, those documents were more specifically for routine operations, but I could be wrong.

But I'm not recalling anyplace where we've actually said we can bound exotics because of the air sampling programs that were in place.

DR. MAURO: You know what, Jim, I think you're right. My experience has also been with a more --

(Simultaneous speaking.)

DR. NETON: You know, like uranium facilities. They had a lot of air monitors out and about the plant, and they were very careful about, you know, controlling it. But the exotics were typically, were sort of the off-normal type situations where they'd be working with, you know, this of course surfaced mostly at the National Laboratory where there would be people off working on their own.

(Simultaneous speaking)

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MR. FITZGERALD: The other thing 6 would find -- this is Joe again, Fitzgerald -- is we wrestled the same question, I think Jim just touched on it, at Los Alamos as well as at Hanford and came up against the same kind of questions as far as how one could model, how could one take what data was there. And I think in all cases it proved to really be a big problem.

MEMBER SCHOFIELD: This is Phil.

I'd like to throw in one thing. Materials that weren't normally classified, I guess, as SNM, when you see a lot of these numbers that doesn't give you the whole amount, because there's some of this material could be held up in residues from the exchange columns, in salts, or just even cleaning the materials in glove boxes.

And since it wasn't accountable, a lot of that wasn't accountable, how much went out in waste, how much was actually recycled back through there? The number you see may be what was the final product, but they actually would have had substantially more than that at the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

other end when they first started.

68

You know, well, Joe knows all about like the MUF accounts and stuff. I mean, when it's not accountable then nobody's really that concerned unless it's a very special material or something. So you can have a substantial, a larger quantity than what you see at the final product.

MR. FITZGERALD: And I'd just agree with that. Yes, you find the MUF, the material unaccounted for numbers in all these inventories including neptunium.

CHAIRMAN GRIFFON: Okay. And just to change the line of questioning a little bit. In your final slide you talked about a potential SEC. Is it just coincidental that both of these kind of, and in '83 was it just the --

MR. RUTHERFORD: No, it seems coincidence, yes. It is coincidental, yes.

(Simultaneous speaking)

MR. FITZGERALD: One thing I would add -- this is Joe again -- you know, on neptunium

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

more than the U-233 is, clearly, the major production operations phased out about that time but there remained an R&D and analysis function that employed neptunium beyond '83.

So that cut point is something that I guess one could examine when this thing comes to sort of closure, to make sure on that cut point. But I think certainly it definitely transitioned in '83.

CHAIRMAN GRIFFON: Well, then what I was getting at, really, was the age-old problem I see at least for neptunium. I don't know if you did for thorium strikes but in neptunium you mentioned buildings, and so the question of who, you know --

MR. RUTHERFORD: How you define a Class.

CHAIRMAN GRIFFON: Is it going to be all workers? Is it going to be -- you know, and we see how much we struggle with trying to do the building kind of -- right. SECs, right.

MR. RUTHERFORD: If you look at how

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

many different buildings that we've identified between the U-233 and the neptunium, and the fact that maintenance workers moved between buildings and the work that they would have done on the glove boxes in trying to define a smaller Class, I think we've concluded it would be all employees.

(Simultaneous speaking)

MR. RUTHERFORD: No, because that's what I said. They're not --

CHAIRMAN GRIFFON: Okay. I would support that, yes.

DR. NETON: I think we've learned from past experience that it's very difficult to administer --

CHAIRMAN GRIFFON: We've all learned that. Okay, all right. Any other questions?

MEMBER KOTELCHUCK: I mean, the argument on neptunium about the operations I recognize, I mean because it just seems like the neptunium exposure is in many different forms,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

right? Airborne, vapors from liquids, et cetera, liquid intakes. I could understand that.

And I guess I didn't catch the argument that not just that it was hard. Hard is not a reason --

(Simultaneous speaking)

MEMBER KOTELCHUCK: Almost, but really difficult to estimate reliably, I assume, it's in there.

MR. RUTHERFORD: I'll work on that portion of my presentation.

MEMBER KOTELCHUCK: Well, I mean, even if I saw years where you might identify a big shipment of something where you could reasonably estimate the neptunium input into the facility and that number was far greater than a kilogram, that to me would be persuasive evidence that not only are the operations difficult, which I will accept, but that the sourcing also is unreliable.

I don't know if that's possible, but

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that would be persuasive evidence to me. 72 MR. **RUTHERFORD:** Okay. Recognizing that uranium and the U-233 issue and the neptunium issue, the years are virtually identical coincidentally as Mark pointed out, the one is, I believe, '62 through '83, and the other is '64 through '83. CHAIRMAN GRIFFON: Any questions on the line? Any follow-up, Phil, or --MR. FITZGERALD: This is Joe. Ι just have a question on when we might see the actual White Papers on those two. MR. RUTHERFORD: Well, Joe, we're not going to have a White Paper on those. going to issue a revised --MR. FITZGERALD: Oh, I'm sorry, the revised ER. MR. RUTHERFORD: We're working to have that, and as I mentioned in the email it probably will not be available until about two weeks prior to the Board meeting. It's just pulling all that information together

1(

11

12

13

14

15

16

17

18

19

20

21

getting the report out, and getting it through classification review.

CHAIRMAN GRIFFON: So that's not too far away.

MR. RUTHERFORD: No. No, it's not too far away at all.

DR. NETON: Everybody's decided neptunium, uranium. And thorium is still being evaluated. That's a little bit harder to --

CHAIRMAN GRIFFON: Well, and that's why I asked about the years for the other, especially the magnesium-thorium, and if --

DR. NETON: Yes, because -- (Simultaneous speaking)

CHAIRMAN GRIFFON: -- fell under this window it may not amount to that much. And I think that might likely be the case with, I mean I'm getting ahead of myself but the tritium question, you know, depending on how this SEC falls, right.

DR. NETON: Some of the other tritium issues would be subsumed --

NEAL R. GROSS

1(

11

12

13

14

15

16

17

18

19

20

21

(Simultaneous speaking) 74 CHAIRMAN GRIFFON: Exactly. But if there's no more on this, thank you for asking the process question, Joe. I was going to ask that too. So a couple weeks before we should have the report, and that's good. And if there's no other questions on this, I think can we take like a ten-minute break and then come back --DR. NETON: Talk about the White 10 11 Papers? CHAIRMAN GRIFFON: -- and introduce 12 13 some of the White Papers, right. Okay. 14 (Whereupon, the foregoing matter went off the record at 10:21 a.m. and went back 15 on the record at 10:36 a.m.) 16 17 MR. KATZ: Okay, I'm sorry. We're five minutes late. This is Rocky Flats Work 18 19 Group, we're back and ready. 20 CHAIRMAN GRIFFON: Okay, Ι think, you know, the next items will be the White 21 22 Papers, and maybe we can just do this back and

This transcript of the Advisory Board on Radiation and Worker Health, Rocky Flats Work Group,
has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable
information has been redacted as necessary. The transcript, however, has not been reviewed and
certified by the Chair of the Rocky Flats Work Group for accuracy at this time. The reader should
be cautioned that this transcript is for information only and is subject to change

forth, you know, start with the tritium issue maybe, or whichever one you want to do first, LaVon. And then the SC&A sort of say what they'd, you know, hook onto these things.

MR. RUTHERFORD: What I had planned was that I thought SC&A was going to give their reviews of the White Papers and then we would talk about the issues that they had come up with. Then I'll also talk about the follow-up efforts that we did as well.

CHAIRMAN GRIFFON: All right.

Well, if Joe -- yes, that's fine. Joe, if you want to start, then either way, yes.

MR. FITZGERALD: Yes, Mark, I'd like to suggest that perhaps the White Paper authors or LaVon could basically review the binning on the separate pieces of the tritium paper, for example, the '73, '74 to '75, then pre-'73, and have discussions in those parts. That's kind of the sequence that we went through.

I think it would allow them in their own words to describe, you know, what approach

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

they took, and then our paper responds to that approach as written. To sort of lead in to what we evaluated, rather than having us basically describe the approach they took. That might be a -- (Simultaneous speaking)

CHAIRMAN GRIFFON: Back to my initial format.

MR. RUTHERFORD: Okay, that's fine with me. And I know that Jim Bogard who is one of the co-authors, and Elizabeth Brackett and Mutty Sharfi, that all three co-authors are on so they will quickly correct me or provide additional information as needed when I get into this.

So basically the tritium exposures, initially the Evaluation Report had identified that we would use the 1973 incident as our bounding scenario for, at that time for all exposures to tritium.

We'd come up with a worst case scenario, taking the worst case bioassay sample from the '73 incident, and originally came up

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

with a maximum dose of 700 millirem. From that then, in the White Paper we went back and looked at, was there ways that we could refine this? Instead of using the 700 millirem over the whole time period, was there ways that we could break this down?

So we looked back and said, well, there's a clear cut point, 1973, when the incident occurred. There's a cut point in the amount of data we have. There's a cut point in this big incident occurring.

And so we decided to break the exposure periods down into a pre-1973 period, like roughly 1959 to 1973, if you assume 1959's the first year of exposure, and then 1973 when the incident occurred, and then post-1973 when we had additional bioassay data.

And so the White Paper breaks down into the pre-1973 period. That was a time period when we had very few bioassay samples. I think a total of six, if I remember, four or six, something like that non-specific as to what they

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

were. It wasn't specific as if they came from an incident or such.

So we had the '59 to '73 period. We had little to no modern data. We have indications that bubblers were in use. Based on our interviews that we had, the classified interviews, we had identified a potential exposure of returned units from Pantex or other sites, mainly Pantex, and shipping containers, opening up these containers and having a release from these shipping containers.

So recognizing that event, we identified this 1974 incident. That was where they opened up the container, had a release, the release was recognized here today. We had monitoring data, bioassay data, and we used that release scenario as our bounding scenario all the way from '59 to '73.

Our basis for that being a pretty good incident to use was when you look at the timeline of when that incident occurred. And I believe it was like the April to September period

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

or somewhere around there, I can't remember for sure.

The incident was being monitored, but we do not believe that the shipping controls, or the controls for shipping containers had really changed since the '73 incident. The '73 incident, remember, was processing a unit. It was not a shipping container being received and opened up.

And so the focus wasn't necessarily on contaminated shipping containers. Contaminated shipping containers, they started monitoring these shipping containers in early 1974, if I remember by the letter correctly, and they went through a campaign of monitoring these shipping containers.

In late 1974, after the '74 incident is when they sent out the letter to the other sites that, you know, basically that they couldn't accept potentially contaminated, tritium contaminated containers because they found that some of these containers contained

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

low levels of contamination.

80

So we felt like this incident was a pretty reasonable scenario for a chronic release in the pre-1973 period, and since we could not define the numbers of releases that could have occurred, we assumed one occurred per day in coming up with our internal exposure approach for that period. So that was the pre-'73 period in a nutshell.

1973, we used the actual incident, and the '73 incident we actually went back and took the bioassay data and came up with a, we fitted the data based on each bioassay and came up with a refined analysis, and I think our numbers came up to around 84 millirem per year the 700 originally that had versus we identified.

And then the post-1973, we have bioassay data that, and if I remember correctly, roughly 75 bioassay samples in the '74-75 time period. We did a coworker analysis based on that data, and that coworker analysis identified

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that there was no exposure, or zero. And so post-1974 we would apply zero for that period.

Let's see, Jim, Liz or Mutty, do you want to add anything to that?

MR. BOGARD: No. That sounds fine.

MS. BRACKETT: Great, thank you.

MR. SHARFI: Agreed.

MR. RUTHERFORD: All right. So I guess we can -- does that help, Joe, to start?

MR. FITZGERALD: No, that's very helpful. And what we did was focus on those three time periods. We kind of took the order a little differently, but we spent some time looking at the -- and we've looked at this before but not perhaps in this detail with the advantage of your analysis.

So what we want to do is take '73 first, and then, for making sense since that was where most of the data started, where we got the initial data that's been used in the past and go from there.

John, Bob?

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

DR. MAURO: Yes, Joe, I'm here. 82

MR. FITZGERALD: You want to throw out the first ball?

DR. MAURO: Okay, I'll carry the relay race. I'll take the first leg. We did start in '73, because I think that's a pivotal year where the realization was that yes, it looks like there might be tritium problems.

You know, prior to '73 there was this assumption -- I don't know how close the Board is with regard to these matters, but it might help, a little background. I'll try to be brief.

The general sense was prior to '73 there really weren't any substantial tritium issues. That the material, the plutonium that was arriving was relatively clean of any tritium. Any tritium was removed.

However, what happened was the State of Colorado had an ongoing water sampling program in Walnut Creek, a receiving water stream from the facility, and you could look at

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

the data. There's data that they have showing the concentration of tritium in Walnut Creek as a function of time as reported by the Colorado Department of Health.

Well, sometime in April, I believe it was, '73, it became apparent that there was a spike. There was a high level of tritium and that triggered a lot of research into, okay, what happened?

And really, I'm repeating a lot of the material that's already in the reports, but I think it's important to understand that this was a sea change. That is, in '73 it became apparent that the material that was arriving at necessarily often, Rocky could, not certainly could contain elevated levels of tritium which could expose workers. So а very large investigation took place to look into this issue. And what happened was that in '73 a major follow-up investigation took place that identified that yes, it was a shipment, I think, that came from Los Alamos that had a problem.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Yes, and they went ahead and togk bioassay samples from 250 workers, very good follow-up urine samples. Did liquid scintillation detection on the samples, and they identified five individuals that had a detectable level of that were of concern, I think they call them action levels.

And action level was any person that had tritium in urine above 10,000 picocuries per liter. It sounds like a big number but it really is not a big number. And that's associated with if you had 10,000 picocuries per liter of tritium in your urine, chronically or continuously, you'd be getting about one millirem a year. So it's not a high number.

But they did identify five individuals. Now, and here's the first problem we have, and I'm trying to get to the issue in '73 that we do need to air out. What happened is the sampling didn't take place immediately after the realization that there was a possible incident in April of '73.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

The bioassay sampling began severage months later, September time period. So what we have here is people that might have been exposed earlier, April, May, June, their bioassay samples were not collected until, oh, several months later, a September time frame, let's say.

And so what we really have is we have five individuals who have fairly thorough bioassay samples but not starting until several months after the exposures may have occurred. And these are the five individuals out of the 250 samples that had the highest levels.

Now, so what was done by the Atomic Energy Commission report, it's this big report that stands behind the White Paper that is being referred to in this discussion that NIOSH prepared, where a detailed analysis is provided of what the -- here's the bioassay results of these workers that started several months later.

They actually plot the concentration of tritium in urine as a function of time when they started sampling, let's say

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

September. And they say okay, given this concentration that we're seeing they could back-extrapolate to the earlier time periods of what the concentrations might have been, and go all the way back to April in some cases, what there might have been. And you can do that and it's easily done.

So now you could actually say, well, we're seeing this concentration of tritium in urine in September. Back in April, the concentrations would have been much, much, much higher as you can imagine just going back in time, because tritium has a ten-day half life.

Well, anyway we have four- to 18-day half life, and ten is sort of like the going number. And it's a good number. Now what happens is, that's sort of like the setup to the story now.

Then NIOSH reported that well, there's a Table A-5 in their White Paper. And by the way, up until this point I was, you know, we were very comfortable with the whole strategy

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that was being adopted here to try to bound <code>%7</code> understand what the high end exposures might have been from this incident. And by the way, we do believe by the way that this incident was a one-of-a-kind, because in other words we don't think incidents of greater magnitude might have occurred before because it would have been picked up by this water sampling program which was quite extensive.

It looked like data was being gathered by the State of Colorado at least twice a month, from the data I was looking at. So they would have picked it up if something big like this happened. Big, I'll call it big, relatively big happened.

So there's good reason to believe that this 1973 incident was a one-of-a-kind incident, was perhaps the most serious incident that had occurred. And now here at NIOSH, and the Atomic Energy Commission at the time and also later now NIOSH try to reconstruct the doses to the workers from this incident.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Now here's where SC&A -- and these calculations were only done a day or two ago. But there's this Table A-5, and this is Issue Number 1. It took a little bit of time to get to it but I had to set the table.

Table A-5 in the White Paper gives NIOSH's estimate of the doses, the time integrated doses, to the five workers that had the highest levels of tritium observed in the bioassay program.

And I went back, and so did Bob, and independent of me we had, really, two people looking at it. And the first one we looked at was Case Number D. Okay, this is one of the workers. And the number that's reported in this Table A-5 of the White Paper is 72 millirem.

Now when we look at the AEC reconstruction of this person's dose, what they say is, listen, you know, it's very difficult to predict what this person's dose is because we're back-extrapolating, and we really don't know when his exposure occurred. It's hard to

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

predict that.

10

11

12

13

14

15

16

17

18

19

20

21

22

89

And so what they do in the AEC papers, they have three different scenarios. They say, well, here's the low end number, and I think they came up with it could be as low as 25 millirem. Then they said here's another estimate that might be a little higher, and they came up with 700 millirem.

And then they say here's our upper end case, and they come up with 2.2, I think it is, rem. And so that late case is the case that assumes the person's exposure may have been as early as April. That is, at the time that the shipment arrived the person might have been working with it and his intake could have occurred very early. And that being the case, when you back-extrapolate, you know, you're going all the way back in time and all of a sudden the intake at times zero could be substantial.

So what we, I guess, we're having a little difficulty with is that gee, it seems to me that if you wanted to place a plausible upper

NEAL R. GROSS

bound on what the highest exposure might have been to this worker, I'm only talking D now, I would have said it's not 72, it's probably more like 2 rem. Not 72 millirem, but 2 rem.

So regarding this issue which is really the starting point for all this is we're having a little trouble understanding the rationale for the doses for A, B, C, D, and H cases in Table A-5.

It seems that the doses were, if you were trying to place plausible upper bound on what the doses these workers may have experienced could have been substantially higher. And keep in mind that, you know, we reviewed this material relatively recently. We actually did the hand calculation, it's a pretty straightforward calculation, yesterday.

And where we're coming out is, we understand the process you went through and we agree with the whole story that's told, but we're coming out with numbers that are quite a bit different than the numbers you're presenting in

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Table A-5, which I believe are the basis for the numbers that you're going to use to assign doses to workers for 1973. And so I guess that's the first issue that perhaps we should talk about.

MR. RUTHERFORD: Okay. Well, I guess we better get some help from Liz and Mutty on this one. I'm not sure.

MS. BRACKETT: Okay, this is Liz.

I guess I didn't see this in your paper.

DR. MAURO: No, I apologize. We reviewed your paper as best we could just about a week ago. You know, it had to go through clearance and everything. And at the time that at least I was looking at it I accepted the numbers that I looked at. I said, listen, I'm not going to go back to the original data and do a lot of calculations. We were trying to get our paper out.

So our White Paper was moving through the system, through DOE clearance, and in the interim we all agreed amongst ourselves, you know, we probably should go back to the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

original source document, the source data, the bioassay results, and see if we can match these numbers. And it wasn't until yesterday.

So quite frankly, when you read our paper, our paper regarding 1973 is very supportive of your work.

MS. BRACKETT: That's what I thought.

DR. MAURO: And it was, until we said, listen, let's go back and do some number crunching and go grab some numbers, and lo and behold. So I'm sorry to spring this to you in this manner, but we are troubled by the fact that gee, we're coming, and not only us, but ironically when I did my calculations it wasn't until later I realized, gee, I came up with 2 rem. And that's exactly an upper bound for Case D. And by the way that's what the AEC report came up with.

MR. STIVER: Yes, this is John. I think the source of the sort of comment at the end of that review where it points out that we

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

This transcript of the Advisory Board on Radiation and Worker Health, Rocky Flats Work Group,
has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable
information has been redacted as necessary. The transcript, however, has not been reviewed and
certified by the Chair of the Rocky Flats Work Group for accuracy at this time. The reader should
be cautioned that this transcript is for information only and is subject to change

were troubled by Case D because we did see the 700 millirem as a chronic exposure for one quarter, and that's what sort of precipitated the, you know, this doesn't quite add up.

MS. BRACKETT: Right. Well, I believe I can explain the discrepancy, and I thought that it was described in this paper. But the AEC paper was done in the '70s. And from what John has said, I gathered that you're just, you said you were doing a hand calculation so you're probably just assuming a ten-day --

DR. MAURO: Yes, as simple as that.

MS. BRACKETT: But that's not the correct model anymore. And there's a 40-day component, which if you're only looking at the samples collected within the week or two after the intake occurred then the use of just strict ten days is fine and you'll get about the correct answer.

But going back to the '70s, they hadn't followed the tritium amount long enough

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

22

Yes.

to see -- it's a small, I don't remember, I thing it's a few percent. But when you start collecting samples months after an occurrence then --

DR. MAURO: Okay.

MS. BRACKETT: -- 40 days makes a difference. And so that's why my values don't match theirs, because of that 40-day component that they don't account for, and I'm guessing that's why they don't match yours. Case D was the one that had the most subjectivity in it, I believe. They had the fewest number of samples, and they were kind of all over the place.

So that one definitely is a bit more subjective as to what the best fit is, but --

DR. MAURO: Liz, let me ask you a question. So you're saying that you used the two component model. You have the rapid release of ten-day half life, and then followed by the slower release excretion rate?

MS. BRACKETT: Yes. And that is the current ICRP model and that's what's in IMBA

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

if you use IMBA to do it.

95

DR. MAURO: Okay, but let me ask you this now. Why would you assume that at that point in time following this intake that occurred over several days that, you're saying that you're into this slower excretion rate component as opposed to the ten-day half life component. It's not intuitively obvious to me that you know that to be the case. And I'll tell you why I say that now.

If you look at the graphs that are presented, this is interesting now. If you look at the graphs that you provide in your report for A through D or H, I forget, the slope at that point looks like a ten-day half life.

And that's what brought me there. I said gee, it looks like, you know, I look at those numbers. I don't know if I have the graph here but I won't burden you with that. But the trigger for me was I looked at it and the fit for a lot of the data looked an awful lot like a ten-day half life. Because remember, the data

10

11

12

13

14

15

16

17

18

19

20

21

were collected, it looked like every few days ogg for about a couple of weeks.

And the slope was, you know, in ten days went down by about a factor of two. So it looked like you were in the mode of clearance at that point in time which was still in the ten-day half life mode of removal and not the slower removal rate that might occur at the back end.

DR. NETON: John. John -- oh.

MS. BRACKETT: Right. It's not like, it doesn't do ten days and then at some point switch to 40. It's just they're both all, you know, apart at the same time.

DR. NETON: John, this is a two-part clearance model, and so you fit the data using the two-part clearance model. It has nothing to do with the early data being ten-day half lives. I mean it's a two-part model.

DR. MAURO: Yes. Well, I hear what you're saying, but I'm just looking at a graph right now. And you follow it for the time period and the slope is a ten-day half life. So you're

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

saying that that slope that I'm looking at fgg the time period that the bioassay samples were taken --

DR. NETON: Is correct.

DR. MAURO: -- is not the slope that was experienced earlier. It was something different. It was flatter.

DR. NETON: No, no. The model predicts that the early clearance is ten days.

DR. MAURO: And it still is when you get to the back end.

DR. NETON: How do you know that?

DR. MAURO: I'm looking at the data right now. Go to Page, I tell you what, go to Page 31 of your White Paper.

Are you looking at that? I'm looking at Figure A-4. I just happened to pick this one. They all look like this. This is Case B as in Boy. And I'm looking at the line and I'm saying, okay, over a ten-day period look like you've got about a factor of two drop in the excretion rate, so it looks like you're in a

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

ten-day half life mode. And so I just went bagks on that basis.

Now I hear what you're saying that the model's more complex, but the data belie that.

MS. BRACKETT: Well, look at the fit. I mean I don't want to argue with you what you think the slopes are, but the model is the model and that's what was used to do the fit. And you can see, and this is a semi-log file and not a --

DR. MAURO: You know, I have to say I do things very simply. I'm looking at the figure. Day 169, and then I go to Day 179 and I see, okay, how much did it drop in those ten days? And it looks like it dropped by about a factor of two.

MS. BRACKETT: Well, okay. But if you look at the overall plot it looks like a straight line, but this is not a linear plot. So it's not dropping linearly.

DR. MAURO: No, I understand what

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

you're saying. But I'm just looking at the reading on Day 169, and you've got a 1.5 times ten to the fifth in this case, and then I go to Day 179 and I'm down considerably.

So I'm just looking at, it looks like about that you've got a factor of two reduction over ten days. Now am I thinking wrong about this? I mean I'd be the first to admit I might be thinking wrong about it, but it seems pretty straightforward. You're in a ten-day half life line here and that goes for every one of these figures.

Now if I got it wrong I'm fine with that, you know, and I'll let go of it. But right now it doesn't make sense to me to say that, you know, this ten-day half life seems to be working.

MR. RUTHERFORD: When you go into IMBA these aren't every day plots. So they're connecting the dots only calculated on the individual bioassay points.

DR. MAURO: Yes.

MR. RUTHERFORD: You have to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

understand it's connecting two points with one straight line. This isn't fitted with every day, so you don't actually see how the curve goes in between points.

CHAIRMAN GRIFFON: Here's what I would propose, John, just for the sake of time today, because this is hard to do, you know, over the phone and on, you know.

DR. MAURO: Yes.

CHAIRMAN GRIFFON: But why doesn't SC&A go and use IMBA and look at this, reassess your own position and then discuss further with Liz or Jim or whoever.

DR. NETON: John, you're suggesting the ICRP model is wrong for tritium, I guess we can be talking about that.

DR. MAURO: Well, I'm not saying, don't get me wrong.

DR. NETON: Well, that's what we're using.

DR. MAURO: I understand what you're saying.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MS. BRACKETT: That is what you have saying.

(Simultaneous speaking)

DR. MAURO: No, wait a minute. What do I do with this data which says that it looks like it's dropping? You know, forget about the line, just look at the --

DR. NETON: But your eyeball fit is not going to show you that John. You need to go back and look at the IMBA. I think you need a little more inspection of the data than just an eyeball fit.

CHAIRMAN GRIFFON: Yes, that's all I'm asking for, John --

DR. MAURO: I'll be glad to do that.

CHAIRMAN GRIFFON: -- is take it back, look at it with the model and then if we need a technical call to follow up.

DR. MAURO: Okay.

CHAIRMAN GRIFFON: That's the way to handle it. It's just hard that we're talking past each other at a certain point.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

DR. MAURO: Yes, I understand2
Well, anyway that's where we are, and I'd be more
than happy to take a, run the data with IMBA, I'll
load up the data with the points and see what
happens then.

CHAIRMAN GRIFFON: That's good.

MS. BRACKETT: Well, and just to caution, IMBA is tricky with tritium because you have to add in some extra, you have to do some finagling to get it to run urine samples.

CHAIRMAN GRIFFON: Liz, can you send your IMBA runs to make them available for SC&A so they can see the runs for this?

MS. BRACKETT: Yes, and I think we have the direction on it. It will do whole-body, so you have to convert whole-body to use it for urine so, but yes, I can --

CHAIRMAN GRIFFON: If you just send the runs that will give him a guideline too.

DR. MAURO: But could I ask you, I mean I will do that but can I ask you something?

And this brings me to what my common sense -- just

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

look at the dots and where they are as a function of time for all of these cases and ask yourself, if I'm going to back-calculate, you know, why would I believe that the slope is going, as the dots themselves, where they show up gives you an indication of the rate at which this is declining.

And you're saying that the rate at which it's declining is different in the earlier models than it is here. I mean that's what you're saying, and that's what you're saying IMBA says. And, you know, I want to think about that. Think about that a little bit too, I mean whether that makes sense or not.

MS. BRACKETT: That's what all of the models are. There's always different parts. It's not that for awhile it's ten days and then for awhile it's 40. They're both simultaneous.

DR. MAURO: Yes.

MS. BRACKETT: It's just that after awhile the 40-day would become more obvious

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

because --104 (Simultaneous speaking) MS. BRACKETT: -- will be, you know, have less of an impact. And so it's not --MR. STIVER: This is John Stiver, if I could just jump in for a second. Why don't we just go ahead and we'll have Joyce take that data, your runs, and she could either use IMBA or AIDE, and do her own independent analysis. DR. MAURO: I agree. That's the 10 way to do it because --11 (Simultaneous speaking) 12 CHAIRMAN GRIFFON: Just for time's 13 14 sake, I think it's helpful, yes. DR. MAURO: Yes, we'll do that. 15 CHAIRMAN GRIFFON: So Joe, maybe 16 17 you can tee up your next --18 MR. FITZGERALD: Yes. Okay, so basically the '74-75, which is the data source 19 20 for the proposed coworker model that would be used, I guess, again for the pre-'73 doses from 21 22 tritium is something that we also looked at in

terms of the 70 data points. And John, do you have a second baseball?

DR. MAURO: Yes, listen, I'll take a shot at it. I don't mind striking out.

CHAIRMAN GRIFFON: He's still got a good arm.

DR. MAURO: I love getting up to bat but I often strike out, although I'm not admitting I'm wrong about the '73 yet. Let me look into that. I'm not ready to give up on that. But I certainly will bow to Joyce's wisdom on this.

Now something interesting happens, and let's talk about '74-75. As I understand it two things happened in that time period and the recognition that there might be some problem with the tritium coming in.

So a program was mobilized where what was done as I understand it is, one out of every ten bioassay sample that was taken for the purpose of plutonium urinalysis was sent off for tritium analysis. So you collected data, and it

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

turns out it was 75 people that were captured that program.

So it was an effort to say, listen, let's keep an eye on this tritium business and see if we come up with anybody that's something unusual. And out of that and out of those 75 measurements, now granted, as you point out correctly, those 75 people that were measured ended up, you know, about one sample, I think, per year. So it wasn't that you had people being followed closely.

But I would be the first to say, listen, you took samples from 75 people over this two-year period and none of them had anything above this 10,000 picocuries per liter. I have to admit that that's a pretty compelling argument that no one's really getting very much tritium exposure in '74 and '75 from that sample. Now, stay with me now. But that's one side of the coin in '74-75. The other side of the coin is that there was this, what we'll call an incident of some type, where some tritium was

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

released. I think it was in August of '74. And there was this follow-up investigation related to that where air samples were collected, bioassay samples were collected, specifically for that incident.

And it appears that there is no relationship between the follow-up examinations that were done to investigate that minor August 1974 incident and the '75 samples collected. It's almost like it's two separate set of activities.

When I looked at the data for the 1974 incident follow-up it appeared that there was a real potential for at least some of the workers that were involved to have experienced doses in excess, have concentrations in urine and that may have inhaled tritium at levels that could have given more than a few millirem from that incident.

I'll say one millirem, two. It's not big, don't get me wrong. We're talking about small numbers here. But it's the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

thinking, the logic sequence that eludes me have now. So what we have is two datasets, and please correct me if I'm wrong if I'm misrepresenting this, but we have two datasets.

One representing the follow-up investigations associated with the August 1974 "incident" where we're getting a data that says, well, some of the workers might have gotten one or a few millirem from that incident, and then you have this other 75 people that were sampled where the highest level of exposure was 0.15 millirem per year. In other words, so clearly there was two different things going on.

In one case you have this what I would say a cohort model where you're looking at a lot of people collecting data and clearly and unambiguously, none of those 75 people received, had any intakes that appeared that even approached one millirem a year. And then you have this other group --

MR. BARTON: John?

DR. MAURO: Yes.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MR. BARTON: Could I interrupt 499 here? This is Bob Barton.

DR. MAURO: Sure, guy, help me out.

MR. BARTON: NIOSH was kind enough to send along the actual data they compiled from the coworker dataset for '74-75, and actually some data points past that. And the statement that nobody had urine concentrations above 10,000 picocuries per liter is not borne out by the data. There are definitely some samples in there. And again, we're talking about one sample per year.

DR. MAURO: Right.

MR. BARTON: So, you know, I'd really like to ask clarification from NIOSH. we went into the claimant records and we pulled together this dataset, and from what Ι understand, and please stop me if I'm wrong, when you had a worker with only one data point in that year, we essentially assumed that they were sampled January 1st of that year and December 31st, and that we came back with that same level,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

and that we just assumed that was their chronig excretion rate for that entire year. Am I correct so far?

MR. RUTHERFORD: I'd have to ask Mutty or Liz to respond to that.

MS. BRACKETT: Unfortunately I did not look at this specifically. Again that sounds correct, but I need to double check on that.

MR. BARTON: Okay. And the only reason I bring this up because, you know, we kind of dug into the dataset, you know, we got it, I think, Monday, and so we've been kind of cracking at it.

And we found at least two cases in the '74-75 time frame that had excretion patterns that if you apply the method in OTIB-11, which deals with, you know, calculating tritium doses, you get some yearly doses that are above one millirem. They're not large but, you know, I think they range from between one and four millirem.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

And then even then there was two cases afterwards in the data afterwards, one case in 1978, I know, and one case in 1981, where if you use the OTIB-11 methodology with the assumption of a constant excretion pattern you would get doses that are, you know, less than ten millirem but still above one millirem. So I guess that's where I became troubled with using this dataset to sort of say, you know, there was no exposure potential.

Now I know one part of this is, and I'd ask for clarification on this as well, it indicates that you used the 95th percentile. And I'm not sure if that means the 95th percentile of the data points, of the log normally fit data points, 95th percentile of the workers for that year. I guess I'd ask for some clarification on that because that may be why, you know, if you look at the 95th percentile maybe you're just under one millirem, but if you actually look at the highest exposed in that cohort of population you will get small doses,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

really, I mean we're talking a couple of millingmy but definitely not zero.

DR. MAURO: I'd like to pick up a little bit on this also in that it seems that the basis for your coworker model are those 75 workers, and notwithstanding the issue that Bob just brought up.

But let's just assume for a moment that whatever the process was using those 75 workers as being the basis for the coworker model to be used not only for '74 or '75, but also for pre-'73, but then you do something that eludes me.

You then say, well, what we're going to assume is that one of these incidents that occurred in August '74 occurs every day, but I don't see any linkage between the bioassay sample of the 75 people and the follow-up investigation of that incident.

So it's a layered problem. It doesn't seem that there is a relationship between the cohort model of '75 and the follow-up

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

investigation of the incident that occurred $_{1}$ in August.

But then you assume that, well, let's assume that we have an August incident every day and we're going to use that, and that's in my mind, of course, that's fairly arbitrary, and make that assumption and apply that to pre-'73.

The multiple layers of concerns that we have related to this whole construct that eludes me as being the logic for it, and one is the separation of these two groups, which they may or may not be but appears that they were, one is this cohort and the other is the follow-up to the '74 incident.

And then there's a question of, okay, now we're going to assign some doses to pre-'73 people where you're assuming that this incident occurs every day. And, you know, why you would pick once a day? That's, I have to tell you, that's where my greatest concern is, this leap that went from what took place in

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

'74-75, and then bring that somehow and apply₁ $\frac{1}{1}$ $\frac{1}{4}$ to how are you going to reconstruct doses pre-'73. You know, it just doesn't line up for us, for me anyway.

MR. RUTHERFORD: John, this is I'll jump in on this a little bit. Ιf LaVon. you look at the interviews that we conducted, the classified interviews, the exposure scenario likely occurred based on those most interviews was opening a shipping container and a release from those shipping containers. was close to that scenario, very close to that scenario, that 1974 incident.

And so the idea here is that, okay, if we had this release, okay, if these releases occurred pre-1973, and we believe that the 1974 incident that controls had not been adjusted, and it was probably that yes, there was more monitoring in place in 1974 but the containers coming in had not changed, in our opinion the sites had not, the information that we've seen so far hasn't supported that the sites had really

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

changed in doing additional work to ensure that shipping containers and shipments coming to the sites were going to have any less contamination at that period in 1974 than they did prior to 1973. So that scenario we felt was a good scenario to cover those earlier years.

The reason we use every day is because we have no basis and no information to support not. If we said, well, obviously this doesn't happen every day if you look at the '74-75 bioassay data it clearly didn't happen every day. But clearly at some point you would expect after they saw the shipping containers were contaminated in 1974 that controls would have changed and sites would have changed and that's supported by that letter.

So we had no basis to come back and say, well, let's use ten per year. Let's use 50 per year. That the only reasonable thing to do was to say that it occurred every day. And remember, that was 0.15 millirem, if I remember correctly, from that release.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

And so, you know, the bounding exposure of what, 37-1/2 millirem is not, you know, it's not substantial, so it seemed reasonable.

DR. MAURO: Okay, I hear what you're saying, and here's where I'm having a bit of a problem. Now let's stipulate just for a moment that the one a day of this type of incident is a good number. You know, I consider it to be somewhat arbitrary, but let's just go with that okay, for a moment.

DR. NETON: It's bounding, John.

DR. MAURO: Pardon?

DR. NETON: Wouldn't you agree it's bounding? Based on the data we've seen, I think it would not have been more than one per day.

DR. MAURO: Okay, I can't say one way or the other but I believe you. But here's the problem. It's not the follow-up investigation from that incident that you're using for your dosimetry. In other words, the 0.15 millirem is from the 75 cohort, not from the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

follow-up investigation from that August 174 incident.

When I looked at the data for that incident I see, now the data's not very good, but I have some air samples. I think we have a few bioassay samples, and the doses are not 0.15 millirem. They're closer to one or greater millirem to the people that were involved in the August 1974 exposure.

So if anything, if we accept the one per day it would not be 0.15 times 365 days a year, it would be closer to 1 or 2 times 365 days in a year. And again I might have it wrong, but I think that you did not use the data from the incident as the basis for your coworker model. You used the data from the 75 people you sampled. And I don't know if there is a good correlation between those two.

MR. RUTHERFORD: I want to ask Jim Bogard, when we did the pre-'73 calculation, which -- and I can't remember, and I guess I could go back and look myself, but what data did we

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

specifically use in coming up with the numbers? MR. BOGARD: There were actually The '75, that's a chronic two populations. The four or five people that were issue. involved in the '74 incident that was a response to an incident. And so the 0.15 millirem is based just on the incident data as I recall. That's a factual piece DR. MAURO: of information where we're disagreeing. Ι didn't read it that way. I might be wrong, but 10 I read that the 0.15 is related to the 75 people 11 while the incident data is substantially higher 12 than that, maybe a factor of ten higher. 13 14 MR. BOGARD: I didn't do the dose I'd have to --15 estimates. DR. MAURO: And certainly this is an 16 17 easy problem to solve. MR. RUTHERFORD: 18 Oh yes, it is. 19 Yes. 20 DR. MAURO: So we could just go take 21 a look at it to see if maybe I got it wrong. 22 MR. RUTHERFORD: Yes, I think this

is --

10

11

12

13

14

15

16

17

18

19

20

21

22

119

MR. BARTON: John, this is Bob Barton. I think when we talk about the 75 claimants that were sampled from NOCTS, I don't think there was ever a number put on there except for the statement that when they evaluated the doses they were all under one millirem. I do believe that 0.15 millirem was associated with the people who were sampled immediately in the aftermath of that 1974 release.

DR. MAURO: Yes.

MR. BARTON: I'm not sure where that number actually came from, whether it was calculated by NIOSH or, I don't think I saw that in the actual documentation.

DR. MAURO: By the way that part of the analysis is in our White Paper. I did the calculation. You guys can take a look at it and see if I did it wrong. In other words I talk about the incident, talk about the air sampling data.

I talk about data that appeared to

NEAL R. GROSS

me that was available at the time fight reconstructed doses to the people involved in this August '74 incident, and I come up with doses higher than 0.15. So again, you know, this is easy to figure out whether I got it wrong or not.

CHAIRMAN GRIFFON: Let me just ask,

I'll try to keep track of these. We're not going

to solve this today so there's a couple action

items already. The first one is John's hand

calculation and having them relook at the

models, and then this one, you know --

DR. NETON: I guess one practical question, this always happens over in the process of adding an SEC is that, you know, we are now proposing that we have an SEC for all workers at Rocky Flats at least from 1962 to 1985.

MR. RUTHERFORD: '83, through '83.

DR. NETON: '62 to '83. So then the question becomes, are these tritium doses which appear to me to be pretty small, are they SEC

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

issues, or is this something that could be tabled as a Site Profile issue recognizing that it's not going to affect anybody's compensability under the SEC? It would affect how dose reconstructions might be performed, unless one wants to say these can be reconstructed and added to the SEC rationale, which I don't I'm hearing is probably warranted.

DR. MAURO: Jim I agree with you completely. I think that if, you know, if an SEC is going to granted based, let's say, on neptunium or thorium that cover these same years, this whole issue we're talking about goes away and it becomes simply a very, very modest Site Profile issue.

DR. NETON: Not a problem with 362.

DR. MAURO: Yes, yes.

DR. NETON: Not a problem. But we still would have a problem to covering 362 for tritium, but this whole thing around the incident and bounding and such is --

MR. KATZ: But just to be clear

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

though, John Mauro, you don't concede whether it's an SEC issue or not based on whether an SEC would be granted for something else.

DR. MAURO: Okay, my apologies.

(Simultaneous speaking)

MR. KATZ: -- decision based on --

(Simultaneous speaking)

DR. MAURO: Okay, okay.

DR. NETON: I think we all understand what we're trying to say here which is if it's a Site Profile issue, if we could all feel that this one's bounded --

(Simultaneous speaking)

DR. NETON: -- or whatever word you want to use, then it's, you know, if we can do something with it then, you know. There's a lot of work going on here, other places that we need to prioritize so this would be --

CHAIRMAN GRIFFON: Yes, it may be lower in the priorities, right. All right, but I am going to keep targeting these actions whether they end up being Site Profile issues or

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

-- right, right.

123

DR. NETON: I guess the question is does this really have to be decided before we go and recommend the SEC, and I don't think it does.

CHAIRMAN GRIFFON: I don't think so, right.

MR. KATZ: Although if you can put to bed these issues it's nice to --

(Simultaneous speaking)

MR. KATZ: It doesn't sound like it takes extensive work to put either of these to bed.

MR. BARTON: This is Bob Barton. Can I make a comment here? I heard, I believe it was LaVon Rutherford say that one of the assumptions sort of backing the use of that 1974 incident is that the conditions, or, you know, the contamination source term, or whatever you want to call it, for that incident would not be decidedly different than that found in the pre-1973 period. Do I have that correct?

MR. RUTHERFORD: Yes, and I think we

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

believe that.

10

11

12

13

14

15

16

17

18

19

20

21

22

124

MR. FITZGERALD: Yes, I want to talk to that, Bob. Yes, this is Joe. Mark, I just said there was three parts to this thing. And the pre-'73, you know, the use of the '74 event, the bounding estimates from that to cover the pre-'73 is something I've been looking at.

And as LaVon knows, I've been a little troubled by how representative that event would be for all the preceding years before '73 for a couple different reasons. Certainly one is it was almost a year between the '73 release and the '74 event.

And I'm certainly concerned that whatever actions were taken operationally, you know, whether it was to control contamination to have the vending site, the shipping sites scrutinized as they were supposed to do, but obviously they failed to do that carefully in the past on the containers that they were sending to Rocky, or frankly, whether, you know, the site was going to monitor carefully before proceeding

NEAL R. GROSS

with handling at the site.

125

These were things that certainly, if not, intuitively I felt there would have been actions taken on an intermediate basis between the '73 event and what took place in '74.

And the importance of that is obviously if we're going to rely on the source term of that particular event and the doses, the bioassays that were taken from it, we need to know that it is in fact typical, which is the, I think, the adjective that was used to describe that event in the NIOSH White Paper.

So that was my going-in concern and there's certainly some other concerns. But let me back up a little bit. You know, one thing about the shipments to Rocky Flats, you know, certainly there was a sense that there wasn't, I think something John said earlier, there wasn't really a tritium exposure issue, per se, at Rocky. Shippers were to screen what they sent, and there were in fact some alarming bubblers to double check to see if there were any

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

releases of tritium when the outer containers were opened, that kind of thing.

So there wasn't a sense it was a big deal. There were some checks in the system procedurally and from a monitoring standpoint to make sure that inadvertent releases weren't a major problem.

Now one thing at Rocky, you had two types of shipments coming in. You had the non-routine shipments, these were shipments that came from places like Lawrence Livermore, Los Alamos, Battelle, Savannah River.

These were materials, scrap, general material that was being sent to Rocky essentially for recycling because Rocky was equipped to handle this. They had the operations and training and were certainly familiar with handling plutonium and other sources, so the rest of the complex tended to send materials to Rocky if it were PU and needed to be processed.

These were considered non-routine,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

so-called SS shipments, and these are the shipments they certainly did have problems with. You know, the rad chem releases that occurred even before the '73 event, plus the '73 event, they were all attributed to shipments from Livermore.

And clearly there was a quality control issue at the lab in terms of what they were sending. These items apparently were contaminated. Just the four that were caught were clearly contaminated.

carefully say that very the four that their because these were monitoring actually did catch in the system and did flag as providing a release in the building, in the plant. The '74 event, similarly, was a non-routine shipment from Battelle Northwest. And I say that somewhat guardedly because there's a document that's on the SRDB, let's see if I can get the number. It's 12460. sorry, no, it's 24165.

But that document reviews the '74

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

event in some detail and basically analyzes 128 as the source of the tritium comes from two possible sources. One being the container that was contaminated that was shipped in from Battelle, the other was entrained tritium in the lines, in the processing lines of Rocky that were remnants of the '73 event.

And as they say in that report, it's very difficult to figure out how much was contributed by what. Certainly they established, there was some residual contamination, tritium contamination in those lines, process lines at Rocky.

So clearly, as far as the source of the tritium it could have come from both the Battelle containers as well as the process lines at Rocky. But in any case, those were all the non-regular shipments, non-routine shipments that were coming in.

As far as containers, who knows? I mean, Battelle, whatever they sent was clearly in whatever form of container that they

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

routinely would send stuff to Rocky. Same with Livermore. Each site, you know, had used their own set of containers. It's not clear how much standardization there was.

But at any rate, so you had a Battelle container coming in that was implicated but not necessarily the only source of tritium for the '74 event. You had Livermore containers implicated in the three releases before '73 as well the '73 release. Now the shipping that's missing from all of this is the routine, the returns that were coming from Pantex. Pantex routinely sent pits as far as returns back to Rocky starting in the '50s, and that went on for decades.

And that was a major part of the operation at Rocky, taking retired, and pits that were taken from dismantled weapons and processing them at Rocky for recovery purposes and what not. That was a much different operation than just taking scrap from Livermore or taking material from Battelle.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

These routinely came in daily over the years. There was residual tritium implicated with them. It wasn't a lot. I think it was felt that you had maybe one or two, and this was based on an interview we had, one or two releases a year that you could actually get picked up in a bubbler in front of an exhaust plenum.

Now I might add that that was an alarming device, it wasn't a measuring device. So it got to the exhaust plenum, you would have an alarm go off as far as the tritium escaping. I might also add that as we heard in our interviews at Rocky that we did together, there's a two-part process.

And I believe this two-part process may have applied, but I don't know for sure from the routine shipments to the non-routine shipments. What they did was basically ship it in two containers. The outer container was opened in an area which did have the tritium monitor in the exhaust plenum, then it was moved to a different room, building, where the inner

10

11

12

13

14

15

16

17

18

19

20

21

container was opened and the pit was in fact put into a glove box for processing. And it was this second step that was not monitored using any tritium monitoring equipment on the exhaust So clearly, the one to two per year plenums. was the, whatever was being measured from the opening of the outer container, not the inner container, which would according to the interviewee would have been where you would have had the higher tritium contamination in any case and where the worker would have been handling the pit and would have been in the proximity of the contaminated container, you know, longer and closer.

I'm just trying to give you this background because I think the operational setting for all this is, you know, it certainly has more ins and outs when you're trying to compare apples to apples and trade a basis for the '74 event being representative to the '50s, '60s and the 20 or so plus years before that.

So I want to go through to some

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

extent, I don't know if it's the same questions on that, but I want to go through some of the factors. And I thought these were good factors.

And, you know, I guess my perspective is I kind of understand the '74 event being characterized as a more typical event with source terms that would be more typical or representative of releases in the past.

The '73 event clearly was from a number of vantage points, unique, extremely characteristic, not so it would be difficult consider that sufficiently to accurate as a bounding approach. Certainly the '74 one at 1.5 curies and the doses we're talking typical, about more but where I'm seems looking at whether stumbling is just circumstances around that release could be seen as representative of the preceding 20-some years of operations.

And, you know, certainly the item about -- I'm going to go through the six factors because I think these are good six factors. I

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

couldn't think of any others.

133

But the six factors in terms of this weight of evidence discussion, the first one which is that the background tritium levels immediately prior to the incident described in the Rocky Flats report was felt to be undoubtedly elevated since the more significant '73 release, were well below dosimetrically significant values can be considered as fairly representative of typical background levels for this analysis.

My problem with that is I'm not sure how one would know what was a typical background. For example, the routine pit returns from Pantex, there are no measurements of the background for those returns.

You do have some sense that the Battelle contaminated container might be similar to the Livermore contaminated container, but I have no idea whether that would be similar to the pit containers.

I would think the containers would

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

different be from the routine versus non-routine, but I'm not even sure they're similar from lab to lab. So there's a question in my mind whether you could actually assume that your background levels of tritium are going to be fairly consistent given the fact you have two different streams of operations and you have three or four different shipping sites involved. So right away I think you have to wonder about And also as I mentioned earlier, in the investigation of the 1974 event it was pointed out that the cross-contamination of the sampling apparatus and the rooms themselves as well as the process lines, you know, in my mind would make any assumption on background for the '74 event problematic anyway.

You know, what is background when you have both a contaminated container as well as contaminated lines, contaminated sampling equipment? I mean the sampling apparatus that they were using for tritium analysis during the '74 event, they found that the sampling

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

equipment was contaminated with tritium. 135

So my sense is that, you know, from a number of different vantage points it would be very difficult to know what the background would be for the '74 event and whether that background compares favorably with all the different other operations that were going on in the past.

I'll take a breath there. Any reaction of LaVon, others?

MR. RUTHERFORD: No, I'm still listening. I mean, you know -- well, I'm not disagreeing with you but I don't think the background is going to overly affect what we've just done from the model we presented.

I don't disagree that, you know, non-routine samples doesn't necessarily reflect what the Pantex returns would be, but I would say that, you know, our additional work that we did we looked for documentation. As you did, we did correspondence with Pantex and Rocky Flats to see if we could find communications between the sites to see if Pantex's containers or shipping

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

containers if their protocols changed and stuff 6 and we couldn't find any indication.

The only indication we found was documents that in later years, in 1980-81 that supported that they made changes then in their program.

MR. FITZGERALD: Yes, I'll get to that in Number 6.

MR. RUTHERFORD: Yes, I know. I'm just saying that, you know, I know where you're going with it, but I'm not sure that I really see that big of a difference right now.

MR. FITZGERALD: Yes. Well, I guess my point is that one wouldn't know. There would be no way of objectively knowing if there's a difference because these differences and some of these unknowns associated with the operations would make it difficult to even compare A to B.

I'm looking for some sense of apples to apples in order to apply the '74 backwards. And the six factors, I think, which kind of are really six good factors, but up to six factors

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

This transcript of the Advisory Board on Radiation and Worker Health, Rocky Flats Work Group,
has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable
information has been redacted as necessary. The transcript, however, has not been reviewed and
certified by the Chair of the Rocky Flats Work Group for accuracy at this time. The reader should
be cautioned that this transcript is for information only and is subject to change

I have problems with probably half of them as figg as one could objectively come to that conclusion or even weighted evidence come to that conclusion.

I think if you look at SRDB, here's a number, 24165, which is the investigation for '74. I think a lot of the questions about Item 1, which is, you know, the reliability of the measurements and knowing a representative background level, sort of comes into better focus in the sense that I think it would be very difficult. So I'll leave that at that and move on.

CHAIRMAN GRIFFON: That's Number 1 you're talking about?

MR. FITZGERALD: That's Number 1.

CHAIRMAN GRIFFON: Okay. If you can, prior to lunch, get through all six that would be great.

MR. FITZGERALD: It goes faster in the middle.

CHAIRMAN GRIFFON: Okay, okay.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

FITZGERALD: Okay. Item 128 The quantity of tritium release significantly less than that released in '73, no argument there. And is probably more typical of potential undocumented releases in work areas for the reasons I just stated I don't think we There's no real good monitoring data for the routine shipments of pits over the 20-plus years that went into Rocky from Pantex. MR. RUTHERFORD: Well, it's more

MR. RUTHERFORD: Well, it's more indicative of a chronic release than the '73 incident. Clearly, we can --

MR. FITZGERALD: Well, as I said earlier, intuitively I would say it's more typical than the '73. Is it in fact more representative of the previous 20-some years? That's the question I have problems with.

And I don't disagree it's more typical, you know, compared with '73. Is it representative enough to be used as bounding for pre-'73? I have difficulty with that. I don't think we have any data for an entire line of pit

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

returns from Pantex.

139

All we have are data points associated with non-routine shipments which are the Livermore and Battelle shipments that in fact had releases. And these are the higher releases. We don't even know given the degree of monitoring that was done at Rocky whether we have all the releases below what ended up being multiple curie releases. I mean the smaller releases that were less than say 50 curies may have been missed entirely, who knows?

Anyway, Item 3 --

CHAIRMAN GRIFFON: Joe, are you questioning whether the '74 data is, the acute incident from '74 is bounding of the potential smaller chronic exposures in the earlier 20 years or --

MR. FITZGERALD: Yes, the chronic and as well as intermittent acute exposures. One, there was no monitoring for that, and two, what data we do have is exclusive to, I would call, non-routine shipments from two labs which

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

are Livermore and Battelle. Battelle was the '74 event, and the rad chem releases that were in that report plus the '73 are Livermore, apparently Livermore shipments.

CHAIRMAN GRIFFON: And the assumption is, as Jim just said that it was, they're applying it daily, right? The '74 incident is assumed to happen every day prior to '73. So are you still questioning that being bounding or then sufficiently accurate?

We don't MR. FITZGERALD: have anything that would be sufficiently accurate. It's comparing these non-routine shipments which certainly you have a source term, but we have no idea how that compares with either a chronic release associated with a daily set, you know, had very frequent, continuous you shipments of pits being returned from Pantex to 20-plus Rocky Flats years how over and representative would that be of those shipments we don't know. We don't have the good data for that.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MR. RUTHERFORD: Okay, I've got 44 quick question, Joe, because it sounds like you're concluding something different than what your White Paper said. I mean if I read the White Paper here it says, "Hence," this is the last sentence on, or it's on Section 5.1, where you basically conclude that the '73 incident would be bounding but our model -- because you say, "Hence, the experience cannot serve as the basis for building a coworker model for pre-'73 exposures to tritium except perhaps to conclude that no worker prior to '73 experienced tritium exposures in excess of 84 millirem per year."

So I mean, unless I heard you wrong you just said that you can't make that conclusion, but the White Paper says you can.

MR. FITZGERALD: Well, I think what we're saying there is that, and that we said earlier that the '73 event stands unique given the amount of tritium that released and what circumstances dotted it.

You know, we're talking elemental

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

tritium versus HTO for the '73 event. So I think there's no question that was a particularly unique and particularly major release. However, and you can correct me, I think the reason you went to the '74 event as your bounding approach is because the '73 event is that unique that it would not, you know, it's like a large number approach.

If you have a large number like that I'm not sure anyone would debate that it would be unlikely you could have an exposure that high and not have it been picked up. In fact, with the monitoring that the EPA had been doing since '69, it would have been picked up from '69 forward.

But the more "typical," and I use that in quotations as the word that was used in the White Paper, the '74 release, that is where I think you do have to come up with an argument that that release bounds pre-'73 because it is representative of the most tritium, elemental tritium that would be released in a container

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

type situation where you had a contaminated container.

And what I'm arguing here is that I don't see how one can make a case of the '74 event being representative enough of what has happened before '73 just because either we don't know or the monitoring was inadequate to give you much of a measurement, and that the operations themselves were diverse enough and different from the '74 event that it would not be comparing apples to apples.

MR. RUTHERFORD: Yes, and I understand. I think I'll add that, you know, our thought was we want to verify that we knew this exposure scenario that was identified in the classified interview, we wanted to verify that that exposure scenario would not exceed what we had originally identified as our bounding incident from the 1973 event.

We were thinking, okay, can this continuous chronic exposure from a release actually come up with exposures higher on an

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

annual basis than what we previously identified from the '73 event?

And so using that 1.5 curie release from the '74 event we felt was a reasonable, or this is a pretty high release, it's from a shipping container, yes, it's not from a Pantex shipping container, and we'll assume it happens every day and see what our numbers come out. And they came out less than that event.

I mean you've got good arguments in that, you know, it's not a Pantex return that typically, I mean that's what 95 percent of what they dealt with was Pantex returns, you're correct there. There is no monitoring data to support anything for pre-'73, you know, we have none. I don't disagree with that. But I think it was a reasonable scenario.

MR. FITZGERALD: No, it's reasonable, it's intuitive, and I think it makes more sense than trying to apply the '73.

MR. RUTHERFORD: Yes, okay.

MR. FITZGERALD: I'm just saying

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that when sort of put to some objective ${\rm test}_{14}$ just find too many unknowns and too many questions because of the operations that were taking place at the time.

CHAIRMAN GRIFFON: Let's hear your other four factors.

MR. FITZGERALD: Yes. Now I know lunch is bearing down on us --

CHAIRMAN GRIFFON: Yes.

MR. FITZGERALD: I'm going to skip what we agreed on. We agreed it's elemental and not HTO. And, you know, as far as the shipping containers we talked about that. That there is definitely some question about the shipping containers not being the same. But let me go to 6, because I did talk to LaVon earlier in this process that I was concerned about the fact that picking '74 where it falls time-wise is almost a year after the '73 became a very public issue at the Pantex.

And having lived in DOE, you know, to have an outside agency find that you're

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

contaminating somebody's reservoir, there 148 almost nothing that would be more dramatic than that.

So my concern was how representative would the source terms we're talking about in '74 be assuming that, you know, Rocky and the AEC would have taken a number of actions precautions in the intervening 10, 11, 12 months to minimize tritium contamination and therefore make the '74 event, while it wasn't an incident again, certainly it would not have been necessarily representative of the kinds of acute releases you might have had before '73.

And one thing I did work with NIOSH on is I made a request of Pantex, made a request of Legacy Management in Denver to look for any specific correspondence that took place between Pantex and Rocky Flats in that time period, that one year time period, to just gauge the level of feedback interaction that was going on.

And in short, we didn't find any actual memorandum or directives, and on one hand

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that would have been helpful to get some fqq; from that standpoint. On the other hand, the AEC didn't always communicate by memorandum and it wasn't necessarily the case that memorandum would have been retained in the file.

So I'll just stop there. I did go back to the SRDB to look for any documentation that would touch on this whole question of in the aftermath of the '73 event what operational actions taken were by management an intermediate basis address tritium to contamination in containers dealing with this problem that Livermore sort of surfaced, which they were sending contaminated items in the containers that went to Rocky Flats and Rocky Flats inadvertently opening them was releasing this.

And in there, there were certainly a number of documents that's referenced in the White Paper. You know, certainly by the fall of '73 both Rocky management and AEC management were putting in place a number of actions. The

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

investigation of the '73 tritium release prompted the AEC to set up an AEC investigation, a very formal investigation from the outside.

That investigation came up with a number of actions and recommendations. And one of the recommendations, Recommendation 2, was to come up with interim control measures for tritium contamination on these off site shipments coming in.

And this is on Page 13 on the top, and what they basically respond -- this was publicized as well. This was issued in a press release that one of the interim control measures was a three-point check coupled with a complete written history applicable to all shipments of material to Rocky Flats.

That was something that they wanted to assure the public they were doing as an interim measure. And they also wanted to tackle more specifically the so-called non-routine SS shipments which the Livermore and Battelle shipments represented and their coming up with

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

actual forms where these forms would specify all the monitoring and, you know, statements of reassurance that they would have to give Rocky that they did due diligence on looking for tritium contamination and any contamination, actually, of the material they were sending to Rocky.

In looking at those forms, and the SRDB numbers are in there, it's pretty clear that the three-point check was looking for just about everything that was coming into Rocky that might have some tritium contamination.

And the non-routine shipping form addressed all of the non-routine shipments that were implicated in these more recent releases, and that form did not have Pantex on it. And it's understandable why it isn't, because it only applied to non-routine shipments.

And there's a memorandum LaVon identified which is the October 21st, '74 memorandum, which seems to suggest that, you know, the site sent a directive, which it did,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

in October of '74 which said, from here on outso you know, we're not going to accept anything until we're ready to do so with a special room where these containers can be opened and monitored for tritium and all of that.

It was like a moratorium on shipments, non-routine shipments not Pantex shipments, but non-routine shipments.

MR. RUTHERFORD: But Pantex was included on that memo.

MR. FITZGERALD: It was included but it applied to non-routine. So I think even though -- and it went to the world by the way, so it went to all AEC operations, but it applied to non-routine shipments which we can confirm further, but based on my reading that non-routine did not include the Pantex pit returns.

But in any case, I think the operational history between the '73 event, and this to me makes sense, because again I had trouble thinking that they took a year before

10

11

12

13

14

15

16

17

18

19

20

21

they sent a directive out to the complex that 194 by the way, you know, we want you to be careful with tritium contamination and supply assurances that you're not sending us contaminated material.

Given what happened in April through, I guess it was the mid-'73, I would have expected the Atomic Energy Commission and Rocky to take immediate action on it, at least an interim basis, to get their hands around this and actually ensure that the sites were checking or following procedures and making sure that when things were received that they were checked, just because of the concern.

This was of course part of the AEC's investigation from the investigation report. So I guess the picture I'm painting is that yes, actually management did do that apparently, and did put in place some interim directives, the three-point process of checking.

They also made it clear to the shipping sites that they were to again follow

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

procedure and monitor what they were sending₁₅₀ Rocky, and that happened in September-October of '73.

So I think this raises some real question about how representative the source term would have been for the '74 event, because again these operational precautions would have been received, would have been listened to, and certainly as a factor in this Item 6 where the argument is that the incident was close enough to '73 that the practices and controls were similar to those prior to '73. And I think they weren't, and logically they wouldn't have been. Certainly actions would have been taken rather promptly and would have been put in place. specific engineering And then more ones, controls would have been implemented a year or so later which is what happened starting October '74. They had a moratorium and were putting into place engineering controls, new facilities, to handle these things more carefully.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MR. RUTHERFORD: Okay. 153

MR. BARTON: Joe, this is Bob Barton. Could I just take a step back and ask a point of clarification? You mentioned a memo in October of 1974.

MR. FITZGERALD: Yes, a memo.

MR. BARTON: I'm also looking at a memo in October 1973, and it's referring to these non-routine SS material shipments, and this thing it went out to everybody, Los Alamos, you know, Battelle, NLO, everybody pretty much.

And I'm just reading here from it and it says, "In order to provide Dow Rocky Flats with sufficient information concerning future requests to receive non-routine SS materials from other AEC contractors, Form," and it gives the form number, "Authorization to Ship SS Material, is being initiated and is required from this day forward." And that is dated October 15th, 1973.

 $$\operatorname{MR.}$$ FITZGERALD: Yes, I referenced that on Page 13.

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

CHAIRMAN GRIFFON: Do you have the document number for that just so everybody has it, Bob?

MR. BARTON: Yes. The SRDB number is 111253 and I'm looking on Page 189.

CHAIRMAN GRIFFON: Okay, thank you.

All right, now I think we got the point. And is there anything else to add? Those were your six factors, although, Joe, I got five. But I'll catch up with you later to get the one I missed.

MR. FITZGERALD: Yes, there was definitely six although I skipped over --

CHAIRMAN GRIFFON: No, that's fine, that's fine. I mean, I think that last one is a very interesting argument to me that, you know, did things change a lot operationally between the '73 event and '74. That would raise a lot of questions on using that later incident for bounding. So I think we've got it. I think NIOSH probably needs time to consider it. Yes.

MR. RUTHERFORD: I just need to look

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

at that. I mean, the question's going to be₁₅₅ or if we go back, we look at it and it appears that controls were put in place prior to the '74 incident that which makes the '74 incident question whether it would be bounding, the overall question is okay, if we can't find another incident and we go back to the '73 incident, which is the, you know, as our bounding thing --

CHAIRMAN GRIFFON: And it's questionable whether that would be plausible so, yes. So I think you run into maybe not being able to reconstruct, but I think you need more time to -- yes, yes.

DR. NETON: I think, really, the issue is small doses.

I don't know. And then if you go back to '62 and we say, okay, what's the shipping status prior to '62, because it's all SEC after '62. If it can't be reconstructed then we'll just give zero tritium dose to anybody in those years, right, I mean that's the idea. It's not

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

sufficiently accurate.

156

But then we'd have to really focus on, well, what was the activity of shipments prior to '62? Can that be reconstructed? See, that's the only open issue in my mind. Otherwise we're going to end up with the conclusion you can't reconstruct tritium doses so we'll just take it away from all workers.

Okay, fine. I'm not sure we need to do that because they're small doses and we can bound that. So we've got to be careful --

MR. KATZ: So you're just saying the point is that you'd be taking it away from people who would require dose reconstructions because they wouldn't be in the Class anyway.

DR. NETON: Exactly. And I think they're smaller --

CHAIRMAN GRIFFON: But also the magnitude of this -- are they going to be a turning point anyway, so you can argue --

DR. NETON: I don't know.

MS. BARRIE: But aren't you using

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

the '74 incident for post-'74 dose reconstruction? MR. RUTHERFORD: No. MS. BARRIE: No. MR. RUTHERFORD: They started monitoring. MS. BARRIE: Okay. DR. NETON: Yes, and so I guess we just need to be careful on how we proceed with that because --10 MR. FITZGERALD: Well, I think the 1: caution also applies to the fact we just don't 12 13 have any good data on the Pantex returns and we 14 can make some assumptions, we can apply what we know on these other types, these few data points 15 we have on the --16 17 DR. NETON: Right, and then we say we can do reasonable dose reconstruction. 18 Well, I'm just 19 MR. FITZGERALD: saying that, you know, it's just one of these 20 things we have to be careful about taking an 21 22 event and applying it backwards.

DR. NETON: Understood. And in ingg mind it's most critical prior to '62 at this point. CHAIRMAN GRIFFON: Well, Okay. let's leave it there. Is that all the issues for the tritium? DR. NETON: I think so. CHAIRMAN GRIFFON: Okay, if that's the case this may be a good break point for -and we'll take lunch. I think we only have the one issue left after lunch. DR. NETON: Falsification. GRIFFON: CHAIRMAN Yes, the falsification issue. But let's --MR. KATZ: Let's try to keep a shorter lunch though if we can. CHAIRMAN GRIFFON: Yes, some people might be able to get earlier flights or whatever. So if we can get back by, I mean, by 1 o'clock, can we --MR. KATZ: So let's try to --

NEAL R. GROSS

CHAIRMAN GRIFFON:

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

10

11

11

13

14

15

16

17

18

19

20

21

22

Back by 1:00,

those on the phone and -- all right, greats

(Whereupon, the foregoing matter went off the record at 12:09 p.m. and went back on the record at 1:00 p.m.)

A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N (1:00 p.m.)

MR. KATZ: So good afternoon, Rocky Flats Work Group. Let me just check on the line to make sure we have our other Board Member. Phil, are you on? Phil Schofield? Are you on the line, Phil? Are you on mute?

Do you want to give him a minute or two before we get started? Phil?

While we're waiting let me just check and see, Joe, do we have you on the line?

MEMBER SCHOFIELD: Ted, this is Phil. I'm on the line.

MR. KATZ: Oh Phil, great. And Joe, do we have you on the line too?

MR. FITZGERALD: Yes, I'm here.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

MR. KATZ: Okay, super. I think then we can get going.

CHAIRMAN GRIFFON: Okay. All right, so we just have the one last item for the meeting today, and I think we should do the same thing. It's with the data falsification concerns, data invalidation. And maybe just let NIOSH tee it up and then let Joe respond, SC&A respond.

MR. RUTHERFORD: Yes, that seemed to work pretty well last time. I'll go ahead and do that.

CHAIRMAN GRIFFON: Okay.

MR. RUTHERFORD: And also at the end of this we'll probably go over some additional items that Terrie had brought up, Terrie Barrie the petitioner had brought up. I want to make sure that we don't forget those, and I'm sure Terrie won't let me forget them. So we'll be all right.

Just a little, kind of go back over the White Paper we put together. Originally,

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Terrie Barrie the petitioner had identified 64 potential concern with data falsification or data invalidation at Rocky Flats, and it was based on the interview that was done with a former employee who had concerns with potential data falsifications. And one area was in Building 123 which was of concern to us because that was the area where bioassay data was We went back through and reviewed the analyzed. through each allegation went paper, responded to each allegation originally with the There was a couple of concerns White Paper. that were brought up at the last Work Group meeting for to try to validate what we had done, and so we did interview two former Rocky Flats workers that, the same workers we interviewed with the neptunium issue we interviewed to try to get a feel for how the health physics program may have been affected by the 1989 raid and what went on there.

Both individuals indicated to us that the only people that were involved with the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

raid you knew because it was done on a need 160 know basis so if you weren't contacted you weren't involved. And since the raid related to environmental issues there was no involvement from the bioassay program perspective.

And accordingly there was no radiological program changes made as a result of the raid. This is coming from one of the interviewees. He indicated that the Department did not know the raid happened until they heard it in the news.

The interviewee also indicated that to this date he has not been informed of any aspects of the raid. That was one of the individuals.

And the second individual -- and I want to qualify these individuals. They are individuals that are part of management, so I want to make sure that that's, you know. Because I know that could be a question and I want to make sure, but these individuals were specific with the RadCon program in that they ran

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

the RadCon program and the bioassay program₆₃

The second employee confirmed that the first interviewee's point that the FBI raid involved specific people and only those who were involved received information about what was going on. He also confirmed the raid was related to environmental issues and not occupational or radiological issues.

And so we got pretty much the same thing from both interviewees. We also went back and we tried to pull together procedures that, you know, from prior years to later years.

We did get one individual that told us that we probably wouldn't find archived procedures, because up until the late '80s or so they didn't archive procedures, they just, you know, when new revisions were made they got rid of the old one.

But we did find some procedures for Building 771 that supported that, I think it was 771, and Dan can correct me if I'm wrong, but that supported that nothing changed, the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

occupational health physics program before the raid and after the raid. So those were just a couple of additional things that we did. And I'll let Ron or SC&A go through their review of the White Paper and then I'll add a couple other things as well.

MR. FITZGERALD: Okay, let me just preface our remarks. You know, our focus, this is something the Work Group tasked SC&A with is looking for evidence of a crossover problem or implication from the environmental side where the allegations rested and the occupational bioassay side.

And we reviewed the White Paper, looked at the references that were in there including the FBI affidavit and the other references that were cited, we reviewed those. And we participated in the interviews that were arranged by NIOSH.

Clearly there were some other documents that LaVon's going to talk to that I think Terrie Barrie had identified that we have

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

yet to actually review.

165

So what we provided in a very brief form I might add, and I'll let Ron go through it, is more or less a status to this point that, you know, we have to this point haven't seen any hard evidence of a crossover but we have not completed this review on the other hand as well. So it's sort of the mid-course, you know, we still have more work to do.

Ron?

10

11

12

13

14

15

16

17

18

19

20

21

22

DR. BUCHANAN: Yes, I'm here. I had it on mute. Yes, this is Ron Buchanan with SC&A. I sat in on one of the interviews and reviewed the other interview. I did not sit in on the one in July but I did the one in August.

And these were interviews with many, many employees like they said, and so we did ask them some questions about the processing of the samples and how often was that, and some of the procedures mainly with neptunium but with other, gross alpha, that sort of thing also.

And from those two interviews we did

NEAL R. GROSS

not get an indication of an issue from the raid However, as Joe as said we have not had the privilege of the other four documents that were brought forth and we haven't seen those yet, and we would like to see those and review those to further our investigation in the area. So that's pretty much where we stand now.

MR. RUTHERFORD: And I'll jump in on that. One of the things that was brought up by Terrie, and I think is Stephanie Carroll as well, was there were four parts to the Tiger Team report and we had one of those parts. There are three other parts.

And I will say, to date we still have not received those other three reports. We've looked for those and we haven't found them yet. I think Joe has even offered to see if he can, you know, find them in some of his areas as well that he has access to and to see if we can get those reports. So yes, we have not received those reports and have not had a chance.

Now one of the other issues was the

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

sealed documents, and I'm going to give you 69 general overview of it and then I'm going to turn it over to Jenny to give you a much deeper.

But generally what the concern was there were sealed documents that potentially contained information that supported that falsification occurred in the occupational health physics program.

And the concern was we didn't have those documents, and since we wouldn't have them we needed to get those documents and see if we could get those documents. So I contacted our general counsel, Jenny, and Jenny took, I'll just let her brief you on what she did.

MS. LIN: Sure. So we did contact our colleagues in the Department of Justice, the U.S. Attorney's office and the Department of Energy, which was a really good place to start.

They have an environmental litigation division, and one of the senior attorneys there happens to be a lead attorney in the Denver's office when the Rocky Flats raid and

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

investigation was going on. So even though she wasn't the person on task she was very aware because their entire office was, you know, assisting DOJ and FBI.

So when we were looking at these sealed documents obviously we need to know what they are, where they are and how to get them. So we were able to answer all three questions.

So these sealed documents were documents provided by the Department of Justice, you know, through the FBI raids, and they were provided to -- actually, let me retract.

So the sealed documents are actually court documents. Those were sealed by the court. Those are different than what we typically think of classified documents and that sort.

So these sealed documents are jury reports, draft indictments, presentments and other court documents, and they were actually sealed by the U.S. District Court for the District of Colorado pursuant to the Federal

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

Rules of Criminal Procedure 6(e). And they have been litigated.

This issue in release of sealed documents had been litigated at least twice and they resolved it in court opinion saying that they cannot be released. So because of that we know that the sealed documents, they would not be available to us.

CHAIRMAN GRIFFON: And you said they include jury reports, draft reports and something else you said.

MS. LIN: I mean these are just the characterization. No one was able to give us the inventories of what these sealed documents are.

CHAIRMAN GRIFFON: Generally though, right.

MS. LIN: So generally. So I looked at the Federal Rules of Criminal Procedure 6(e) to see what type of documents fall under that category and also look at the court's opinions, and they're pretty consistent in terms

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

of the type of document that was sealed by the court.

And then obviously there's ongoing investigation so they're assuming for the courts to seal those documents. And I think at least one of the jurors had written a book about their experience.

But I think an outcome of this investigation by the Office of General Counsel is that we were able to have these concurrent statements from the DOE's litigation division and also from others who were doing the data capture that is pretty consistent with the source documents that were evaluated by the grand jury, have been gradually released to either the Rocky Flats plant when it was still in operation or to DOE.

And I think our data capture team also confirmed that's actually the case with the person who is maintaining the data. So it seems like the story that OGC is getting actually confirm, matched up with what the data capture

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

team -- 171

MR. RUTHERFORD: Yes, basically, and as Jenny mentioned, the source documents, the documents that they were using to evaluate, guess, these legal issues, the documents of have been, those some were classified and they were returned to Rocky Flats.

And there's actually an inventory sheet of those documents that were, you know, taken and then returned over time, and the Denver Federal Records Center has confirmed that they had those documents and we have those documents.

So the only outstanding one is the three reports that are still from the Tiger Team that we still have been unable to find at this time.

MS. BARRIE: So the documents that were returned by Justice is in the SRDB?

MR. RUTHERFORD: They would be, either they have them in the Site Research Database or they're at the Denver Records Center

NEAL R. GROSS

10

11

12

13

14

19

16

17

18

19

20

21

and we can get them. But I believe we've qob them all because, in fact I know we do because we had a data capture with the EMCBC locally in Cincinnati where some additional documents that were sent that were part of that and we retrieved those documents. So Dan, correct me if I'm wrong. Dan Stempfley.

MR. STEMPFLEY: What you're saying is how it is. We did identify and collect the pertinent documents that we were looking for.

MR. RUTHERFORD: Yes. Okay, thanks.

CHAIRMAN GRIFFON: So you have all the documents that run inventory to this? Okay.

MR. RUTHERFORD: Yes, the only thing we don't have is the three reports that they have identified.

CHAIRMAN GRIFFON: Right. Got that, right. The three parts of the Tiger Team report, right? Okay.

MR. RUTHERFORD: Yes, and I don't understand why we don't have this. It just

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

seems like that would be something easy for $_{1}$ $_{7}$ $_{8}$ to get --

CHAIRMAN GRIFFON: Yes, that should be easy.

MR. RUTHERFORD: -- that we haven't been able to get.

MS. BARRIE: Well, that makes me feel better because I've been waiting years to try to get my, I've filed FOIAs two or three times on them and --

CHAIRMAN GRIFFON: So when -- I'm sorry. When Joe at the end of his description mentioned, or maybe it was Ron said the other four documents that they're still waiting to see?

MR. RUTHERFORD: I think he was talking about the three --

CHAIRMAN GRIFFON: The three parts of that, okay. I think that's what he was referring to.

MR. RUTHERFORD: Is there a fourth one I'm missing, Jim?

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

MR. FITZGERALD: I think that I bioassay procedures was another item that I think Terrie had cited in one of her --

MR. RUTHERFORD: Yes, I actually, we have an updated White Paper that I didn't want to send it out, you know, at the 11th hour type thing because it came out, it just cleared ADC review yesterday and it hasn't been reviewed internally by us. So it does cite some additional Site Research Database documents for you to look at. So when you get your hands on that you can look at that in comparison.

MR. FITZGERALD: And on the three documents that we're missing, I think I even mentioned this to Terrie at one point, I will, you know, sort of beat the bushes at DOE headquarters both in the program office, safety office as well as in their archives to see if I can find them.

I know they have complete sets of the Tiger Team reports. The Rocky ones were not officially a Tiger Team so they should be there

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

as well. 175 MR. RUTHERFORD: I thought maybe you'd have it on your shelf or something. MR. FITZGERALD: You would think. I actually didn't do that one. I did the one right afterwards. MR. RUTHERFORD: Okay. DR. BUCHANAN: This is Ron with SC&A and I had some questions for you. You know, one of the four documents was HP procedures, one was 10 environmental and the other three you haven't 11 been able to get yet, and then you talked just 12 now about some new court documents. 13 14 Can you email me those documents 15 that you do have? The HP procedure, the environmental and the new documents, or give me 16 17 the --MR. RUTHERFORD: SRDB numbers? 18 DR. BUCHANAN: -- SRDB number by 19 20 email so I can look them up? 21 MR. RUTHERFORD: Yes, I will. 22 hopefully we can get this revised report

released real quickly, but I'll get you all the information. We also have inventory sheets from the documents that were taken as part of the raid. And I'll get you access to all that information.

DR. BUCHANAN: Yes, if you could email that directly to me I'd appreciate it so that I can start working on that.

MR. RUTHERFORD: Okay, no problem.

CHAIRMAN GRIFFON: And just to be clear just so I didn't miss something, the review of the sealed, you know, the court documents, all source documents were returned to the site, right, and it was inventoried and NIOSH has all of those?

MR. RUTHERFORD: Yes.

CHAIRMAN GRIFFON: I think that's the critical part, yes.

MEMBER KOTELCHUCK: Let me be clear. The allegation was that environmental data was manipulated or falsified. Is there any allegation that the occupational health data was

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

falsified, or is that just a concern because the people who measure the one measured the other? MR. RUTHERFORD: Yes, that's the And I mean, Terrie can correct me if I'm wrong, but we didn't see anything specifically of allegation the that the occupational health, you know, the bioassay data for the occupational health physics group was ever in question. MS. BARRIE: if Yes, and remember during the public comments during the July meeting, there was a Rocky Flats worker who 12 filed a grievance through the union on that Building 123 was changing their doses. MEMBER KOTELCHUCK: A-ha. So there is an allegation within the union --MS. BARRIE: Right. MEMBER KOTELCHUCK: and grievance procedure. MR. RUTHERFORD: I'm glad brought that up because that is another thing

NEAL R. GROSS

that we are following up on. We are doing an

10

11

13

14

15

16

17

18

19

20

21

This transcript of the Advisory Board on Radiation and Worker Health, Rocky Flats Work Group,
has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable
information has been redacted as necessary. The transcript, however, has not been reviewed and
certified by the Chair of the Rocky Flats Work Group for accuracy at this time. The reader should
be cautioned that this transcript is for information only and is subject to change

interview, classified interview with that individual. We've been working on that. It kind of got held up a little bit.

One, scheduling a classified interview is not easy especially depending on the location the individual is and whether we have somebody out in that area to do it and such.

But we're working on that and so we're going to interview that individual because they requested it be in a classified area which is good. That means they can tell us a lot of things.

So we're going to complete that interview. We'll see if we can get Ron Buchanan or somebody from SC&A to be involved in that as well, and then we'll go from there on that.

CHAIRMAN GRIFFON: And can you clarify? Building 123 that Terrie referenced, that was the bioassay lab or was it -- did it do all --

MR. RUTHERFORD: Well, environmental samples and --

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

CHAIRMAN GRIFFON: And occupational or bioassay samples, all right. Both, okay. But they weren't MR. RUTHERFORD: done by the same individuals or group. in the same building. CHAIRMAN GRIFFON: In the same building but separate, okay. MR. RUTHERFORD: Yes. CHAIRMAN GRIFFON: Joe, do you have anything to add? 10 MR. FITZGERALD: No, like I said, I 11 think we will seek those missing documents and 12 continue our review and try to get back to the 13 14 Work Group. MR. RUTHERFORD: Yes, there is one 15 other thing that Terrie brought up that I 16 followed up on, and it's not related to data 17 falsification, but if I don't tell it now I'll 18 end up forgetting. 19 20 So one of the issues was a concern of tritium stripping. And you guys might 21 22 remember an email questioning of what is this

tritium stripping, and it was identified. 18 believe it was identified in our SEC-0030 Evaluation Report. It was also identified in an email exchange that we had internally.

And that was a typo and I've provided SC&A, or Joe anyway, Joe Fitzgerald with SC&A, the SRDB reference that should have been titanium stripping and not tritium stripping. And I've given him the SRDB number and the chem risk report number that references that.

MR. FITZGERALD: Yes, I have that.

MR. RUTHERFORD: Okay.

CHAIRMAN GRIFFON: Terrie, did you want to add or comment anything on this file or overall comments?

MS. BARRIE: I have overall comments, yes.

CHAIRMAN GRIFFON: Okay, well, hold those for a second just to make sure. Is there anything else on this topic on the phone or here in the room? Because I think it's still a work in progress. Obviously we have several things

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

to find in this review. Okay.

181

All right, so then yes, Terrie.

MS. BARRIE: Okay.

CHAIRMAN GRIFFON: I think at this point we've wrapped our -- you can make comments, yes.

MS. BARRIE: Right. I just want to thank everybody for all the work they've done. I mean, it's been a long hard road getting to this point of especially pointing out that oh, what about this thorium strike and what about this and what about that?

And I really appreciate everyone's interest and investigation. I honestly do, and I'm quite thankful that you are recommending an SEC for, you know, certain years and including all the workers.

When it comes to the -- and I hope that the full Board votes for it too obviously. When it comes to the falsification, this has been one of my sticklers because I have my husband's documents where there are erasures and there's

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

cross outs, and so that's how I first 985 involved with that.

You know, I don't know if he was exposed to uranium 238, 235 or 233, because it's whited out. But that's that. And I think I sent an article or a report from 2006 from the former worker program, and I found one from 2004.

And this is why I keep getting back to the falsification, how important this is.

And I'll give this to you too. It says this is for the former worker program eligibility criteria.

And the very last criteria on this list here, the reason that the former workers from Rocky Flats were invited to participate is because a review of their exposure or work record indicated significant likelihood that an internal deposition or external dose may have occurred that was not well evaluated in the past. Okay, to me that says, oops, we made a mistake on our dosimetry records and our testing.

So this is, like I said, a 2004

NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

paper. So I do appreciate you not closing this out, and I hope that we can resolve that in the next few months after the meeting.

And what really bothers me about this was it was authored by a Site Profile author back then and he knew this when, you know, he was authoring the Site Profile. So if you'd like to see this or -- okay. But thank you everyone. I do appreciate everything.

CHAIRMAN GRIFFON: Thank you.

Yes, and I think that grievance in particular is a good one that we really need to follow up on.

So any other public comments before we close?

Okay, so I look forward to the report a couple weeks before the Board meeting hopefully.

MR. RUTHERFORD: Yes.

CHAIRMAN GRIFFON: The updated report and your presentation in Denver. And thanks for all the hard work by NIOSH and SC&A. All right, so meeting adjourned.

(Whereupon, the foregoing matter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

went off the record at 1:26 p.m.)

184

NEAL R. GROSS

10

11

12

13